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ABSTRACT

THE IDENTIFICATION OF LONG NON-CODING RNA ZFAS1 THROUGH AN
EXPLORATORY RNA-SEQUENCING ANALYSIS AND ITS ASSOCIATION WITH
EPITHELIAL-TO-MESENCHYMAL TRANSITION IN COLON
ADENOCARCINOMA
Stephen J. O’Brien
November 7th 2019
Colorectal adenocarcinoma is the fourth most common cancer diagnosed worldwide and
is a significant cause of morbidity and mortality. This dissertation performed an
exploratory RNA-sequencing analysis comparing gene expression between colon
adenocarcinoma tissue and paired normal colon epithelium. After identification of a
number of lncRNAs that were increased in expression in colon adenocarcinoma
compared to normal colon epithelium, we aimed to validate the expression and
investigate their function in vitro. Specifically, we focused on the lncRNA ZFAS1 and its
association with epithelial-to-mesenchymal transition.
These studies found the following:
1. Seven candidate lncRNAs were identified from the exploratory RNA-sequencing
analysis to be significantly increased in expression in colon adenocarcinoma, three of
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which ZFAS1, GAS5, and PVT1 were found to be significantly increased in colon
adenocarcinoma compared to paired normal colon epithelium as examined by laser
capture microdissection.
2. Both ZFAS1 and GAS5 are significantly increased in cytoplasm of cell lines compared
to the nucleus, whereas PVT1 was more represented in the nucleus. As such there was
significant knockdown of both ZFAS1 and GAS5 following transfection with siRNA.
3. Knockdown of ZFAS1 leads to decreased proliferation and migration in colon
adenocarcinoma cell lines. In contrast, knockdown of GAS5 did not lead to a change in
proliferation. We focused our subsequent investigation on ZFAS1.
4. ZFAS1 has a reciprocal relationship with miR-200b and miR-200c expression in vitro
but not with three of the other experimentally verified miRNAs that bind ZFAS1. We
also validated the functional effect of miR-200b and miR-200c mimics on decreasing cell
migration.
5. ZFAS1 knockdown is associated with the functional changes on cellular phenotype
through decreasing ZEB1 expression through miR-200 signaling, causing a subsequent
increase in the expression of the epithelial marker, E-cadherin, and a decrease in the
expression of the mesenchymal marker, vimentin.
These findings demonstrate an association between ZFAS1 and miR-200/ZEB1/Ecadherin, vimentin signaling in EMT signaling in colon adenocarcinoma. In contrast to
typical EMT signaling, ZFAS1 knockdown also leads to decreased cell proliferation
suggesting its potential value as a therapeutic agent.
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CHAPTER I

INTRODUCTION- COLON AND RECTAL CANCER

a)

Epidemiology and diagnosis of colorectal cancer in the United States
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the

United States and is the third leading cause of cancer related deaths.1 In 2018, there were
approximately 140,000 new cases of colon and rectal cancer in in the United States, and
approximately 50,000 deaths from colon and rectal cancer combined. A majority of
patients present with advanced stage (lymph node disease or distant organ metastasis), in
whom the risk of recurrence is high and the overall prognosis is poor (Figure 1).1,2 The
relative 5-year survival for stage I CRC, however, is 92%. The 5-year survival for stage
IIA and Stage IIB are 87% and 63%. The 5-year survival for stage IIIA, Stage IIIB, and
stage IIIC are 89%, 69%, and 53%, respectively. The 5-year survival for stage IV disease
is 11%. Although screening for colon and rectal cancer has been shown to improve
survival, many patients are still diagnosed with advanced stage disease at initial
presentation (Figure 2).3
In the United States, cancer staging is guided by the American Joint Committee
on Cancer (AJCC)4 TNM staging. TNM refers to Tumor, Node, and Metastasis staging.

1

This indicates the degree of invasion into the bowel wall, the presence of lymph node
involvement, and the presence of distant metastasis, respectively. Previously, the Duke’s
classification system had been long used for colorectal cancer staging, which was
subsequently modified to the Astler-Coller staging system.5,6 These staging systems align
with that of the contemporary TNM system (Table 1). Accurate staging is essential for
assessing patient prognosis and deciding on the most appropriate treatment regimen.

b)

Molecular pathophysiology of colorectal cancer
The underlying etiology of CRC is complex and heterogeneous, but here are three

major types of colorectal cancer; sporadic, inherited, and familial. Furthermore, there are
three major pathways of pathogenesis that underlie the development of colorectal
adenocarcinoma, but overlap exists between these pathways in patients. They include
chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island
methylator phenotype (CIMP).
The CIN pathway is commonly known as the adenoma-carcinoma sequence. 7,8
This pathway consists of a number of progressive “genetic hits” in normal colon
epithelium, to produce an adenomatous polyp, and which eventually leads to an invasive
adenocarcinoma. Classical mutations in this pathway consist of mutations in genes and
signaling pathways such as APC, KRAS, TP53, TGF-β and PIK3CA.7 This adenomacarcinoma sequence is supported by a number of clinical studies that demonstrate a

2

Figure 1. Temporal changes in 5-year overall survival for colon and rectal adenocarcinoma stratified by disease stage in the United
States 1975- 2012

3
Although there have been improvements in overall survival for colon and rectal adenocarcinoma over the different time periods, the
survival for patients with regional or distant disease at diagnosis remains poor.
Modified from: Siegel RL, Miller KD, Fedewa SA et. al. Colorectal cancer statistics, 2017. 2017;67:3 177-193 and Siegel RL, Miller
KD, Jemal A. Cancer statistics, 2019. CA: a cancer journal for clinicians. 2019;69(1):7-34.

Percetnage of Overall
Cases

Figure 2. Distribution of colorectal cancer cases by stage in the United States 2009- 2015.
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Modified from: Sheets SSF. Colon and Rectum Cancer. Cancer Statistics: Statistical Summaries National Cancer Institute. 2015.
Available from: https://seer.cancer.gov/statfacts/html/colorect.html [Accessed 4th September 2019].

Table 1) AJCC 8th edition staging for colorectal cancer and alignment with Duke’s
staging and Astler-Coller staging4,9

Stage

Primary
Tumor
(T)

0

Tis

Regional
Lymph
Nodes
(N)
N0

1

T1

N0

M0

A

A

T2

N0

M0

A

B1

IIA

T3

N0

M0

B

B2

IIB

T4a

N0

M0

B

B2

IIC

T4b

N0

M0

B

B3

IIIA

T1-T2

N1/N1c

M0

C

C1

T1

N2a

M0

C

C1

T3-T4a

N1/N1c

M0

C

C2

T2-T3

N2a

M0

C

C1/C2

T1-T2

N2b

M0

C

C1

T4a

N2a

M0

C

C2

T3-T4a

N2b

M0

C

C2

T4b

N1-N2

M0

C

C3

IVA

Any T

Any N

M1a

D

D

IVB

Any T

Any N

M1b

D

D

IVC

Any T

Any N

M1c

D

D

IIIB

IIIC

Distant
Metastas
es (M)

Dukes’
Stage

AstlerColler
Classification

M0

-

-

Tis: Carcinoma in situ, T1: Invasion into submucosa, T2: Invasion into muscularis
propria, T3: Invasion through muscularis propria, T4a: tumor invades through the visceral
peritoneum, T4b: Tumor invades or is adherent to adjacent organs. N0: No lymph nodes
metastasis, N1a one lymph node positive, N1b two-three lymph nodes positive, N1c: tumor
deposits in subserosa, mesentery, N2a four to six lymph nodes positive, N2b: >7 lymph nodes
positive. M1a: metastasis to one site of disease, M1b: metastasis to >2 sites, M1c: Metastasis to
peritoneal surface alone or with another organ metastasis
5

progression of adenomas to invasive adenocarcinoma.10,11 In addition, recent gene editing
based studies support this hypothesis which introduce progressive mutations through
CRISPR-mediated gene editing to produce an invasive adenocarcinoma from normal
intestinal organoids.12 In this study, only organoids derived from adenomatous tissue, and
not from normal colon epithelium, could lead to the development of macro-metastasis in
an in vivo model, which suggests that other signaling factors beyond that of mutations in
classically associated genes are a major driver for metastasis.
Microsatellite instability is involved in the pathogenesis of 15-20% of colorectal
cancer.13 This pathway consists of mutations in the genes that are responsible for
repairing base mismatches in cellular DNA. 14,15 In all cells, mistakes can occur in DNA
replications which leads to the occurrences of mismatches between DNA base pairs. In
cells with a normal mismatch repair system, this can be repaired to eliminate the
mismatch, but in cells with a defective system, this repair does not occur and can lead to
the progressive accumulation of mutations in genes. Most commonly, this occurs,
through genes such as MLH1, MSH2, MSH6, or PMS2. The most commonly observed
phenomenon amongst these genes is that of epigenetic silencing of MLH1 through
promoter hypermethylation.16 Hereditary Non-Polyposis Colorectal Cancer, also known
as Lynch syndrome, is a familial form of colorectal cancer, that occurs through an
autosomal dominant germline mutation in one of the previously mentioned mismatch
repair genes.
Epigenetic modification of cells can occur through the methylation of CpG base
residues. A CpG residue is the occurrence of a cytosine base adjacent to a guanosine base
in DNA. In the promoter regions of genes, CpG residues can cluster into areas called
6

CpG islands which, when methylated, can lead to silencing of the gene.17 In the case of a
tumor suppressor gene, this can promote carcinogenesis, even in the absence of a
mutation within the gene sequence. The sessile serrated polyp pathway is thought to
account for 20% of sporadic colorectal cancers. It shares a similar multi-hit pathogenesis
as the CIN pathway, but is distinct in that KRAS and BRAF mutations are common, with
the addition of the CpG island methylator phenotype to produce a microsatellite
instability.18,19
Although there are a distinct signaling pathways, as outlined above, an individual
patient may have some elements of different pathways leading to colorectal cancer
(Figure 3). Furthermore, there appears to be an association between the anatomical
location and the spectrum of mutations of colorectal cancers. Right- sided colon
adenocarcinoma tumors are more likely to be highly microsatellite instable tumors,
whereas left-sided colon adenocarcinomas are more likely to be chromosomal instable
tumors.20 BRAF mutations more commonly occur in colon adenocarcinomas, and rectal
adenocarcinomas typically have APC and TP53 mutations.21 This adds to the complexity
of treating patients with colorectal cancer.

7

Figure 3. Schematic representation of several overlapping pathways involved in the development of colorectal cancer

8
Red circles represent mechanisms based on tumor suppressor and mutator pathways. Blue circles represent mechanisms based on the
precursor lesion (CIN and Serrated polyp pathways). Yellow circles represent currently poorly characterized pathways.
MYH- mutY DNA glycosylase, TSA- Traditional serrated adenoma
Snover DC. Hum Pathol. 2011;42(1):1-10

c)

Contemporary treatment of colorectal cancer and current challenges
Treatment for colorectal cancer is guided by the National Comprehensive Cancer

Network in the United States.22 Surgical resection of the tumor is the principle treatment
for colorectal cancer, which may be supported by other therapies including chemotherapy
and radiotherapy depending on the tumor location and stage. In the case of advanced
adenomas or early stage tumors, these may be amenable to local excision with
endoscopy, or through transanal excision in certain cases.23
Treatment strategies for advanced stage (Stage III or Stage IV) colon and rectal
cancer are different in the case of neoadjuvant and adjuvant chemotherapy and
radiotherapy. In the case of colon adenocarcinoma, adjuvant postoperative chemotherapy
is recommended for advanced stage tumors or localized tumors with certain high-risk
features (poor differentiation, lymphovascular invasion, perineural invasion, bowel
obstruction, <12 lymph nodes examined, localized perforation, or close/positive
margins). In the case of rectal adenocarcinoma, preoperative chemoradiotherapy is
indicated for tumors beyond a T1-T2, N0 stage.9 Additionally, postoperative
chemoradiotherapy may be indicated for high-risk cancers. For both colon and rectal
adenocarcinoma, the chemotherapeutic agents that are used include 5-flurouracil,
capecitabine, oxaliplatin, and irinotecan. However, advances in the understanding of
tumor biology has led to the use of small molecule therapies which target specific
signaling pathways involved in epidermal growth factor signaling (e.g. cituximab),
vascular endothelial growth factor signaling (e.g. bevacizumab), or immune cell
recognition of cancer cells (e.g. Nivolumab).

9

Surgical treatment for colorectal metastases can be carefully decided in a
multidisciplinary fashion, as in the case of colorectal liver metastases24,25 or in colorectal
lung metastases.26 As an adjunct to surgical resection, microwave coagulation therapy or
radiofrequency ablation therapy can be considered. As metastatic disease is the principle
disease-specific cause of death from colorectal cancer, it is important to study the process
of how tumors transition from locally proliferative in the colon, to developing an ability
to become metastatic. A critical aspect of this process is epithelial-to-mesenchymal
transition, and improved understanding of this process may assist in the development of
more effective therapies for colorectal cancer.
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CHAPTER II

EPITHELIAL-MESENCHYMAL TRANSITION IN CANCER

a)

Introduction- Role in Normal Embryological Development and Cancer
Epithelial-Mesenchymal Transition (EMT) is a cellular mechanism that has long

been recognized as a central feature of normal cellular development.27 A number of
important components of embryological development are reliant on EMT such as that of
gastrulation, neural crest formation, and heart morphogenesis.28 Over the past 20 years,
there has been significant research into the process of cancer metastasis and EMT has
also been recognized to have a major role in its development.29

b)

Role of EMT in Cancer
EMT is the process whereby cells lose their morphological and functional

epithelial features and gain a mesenchymal phenotype, through differential gene
overexpression and repression 30,31. At a macroscopic level, this is the process whereby
locally proliferative cancer growing in the bowel mucosa, gains the ability to invade from
11

the mucosa towards the bowel serosa, to the draining lymph nodes (Figure 4). At a
cellular level, EMT is a complex process whereby epithelial-like cells lose cell polarity,
cell-to-cell adhesion, and gain a migratory and invasive phenotype (Figure 5).32 This
process consists of a series of molecular changes that are essential to occur to facilitate
cancer metastasis.29,33
There is clinical evidence to support that intra-tumoral differences exist in the
expression of epithelial and mesenchymal markers.34 At the deep border of tumors in the
wall of the colon there is relatively reduced expression of epithelial markers such as Ecadherin, occludins, and claudins, and an increase in markers such a vimentin, Ncadherin, and fibronectin.34,35 This indicates that cells which are at the deep border, or
invasive front of a tumor have a more mesenchymal phenotype. Interestingly, EMT is
reversed when cancer seeds, and develops at a metastatic site. Colorectal liver metastasis
has been shown to recover epithelial marker expression and lose vimentin expression.36
This reversion process is called mesenchymal-epithelial transition (MET) in cancer.
There are a number of critical mediators of both EMT and MET in cancer, which affect
these processes at both genetic and epigenetic levels.

c)

Regulators of the EMT process through genetic and epigenetic processes
Genetic regulation can occur through transcription factor regulation via factors

such as Snail Family Transcriptional Repressor 1 (SNAI1), snail family transcriptional
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Figure 4. Illustration of the macroscopic events of EMT that contribute to the change from a locally proliferative cancer to an invasive
and metastatic cancer.

13

As cancer cells grow locally, there is a switch to a mesenchymal phenotype and the deep border, which invades through the basement
membrane to metastasize to the lymph nodes and in distant organs. At the new metastatic site, the cancer cells revert to an epithelial
phenotype to proliferate.

Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation. 2009;119:1420-8.

Figure 5. Illustration of the cellular events that contribute to the process of EMT to
promote a metastatic cancer.

There are a number of cellular changes that occur to change locally proliferative
epithelial cells to more mesenchymal cells, which have the ability to migrate and invade
through tissue.

Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal
transition and implications for cancer. Nature Reviews Molecular Cell Biology.
2019;20:69-84.

14

repressor 2 (SLUG), Zinc finger E-box-binding homeobox -(ZEB)1, and ZEB2.37,38
These factors can directly induce the transcription of epithelial adhesion and cellular
polarity genes and repress that of mesenchymal cytoskeletal and metalloproteinase genes.
Epigenetic regulation of EMT can occur through different processes involved in
methylation and acetylation.39,40 Methylation at CpG islands of the promoter region of
genes involved in EMT repression has previously been demonstrated.41 Treatment with a
demethylating agent has been shown to induce an epithelial-like phenotype in vitro in
both naïve and chemoresistant cell lines.36,42
The field of non-coding RNA represents an expansive avenue of research for
EMT, as both microRNA (miRNA) and long non-coding RNA (lncRNA) are significant
mediators of this process.40,43 MicroRNAs (miRNAs) are a major regulator of cell
function through specific interaction with RNAs to inhibit protein translation or to induce
RNA degradation. miRNAs are small, naturally occurring, non-protein coding RNA
molecules that are approximately 20 nucleotides in length. miRNAs are transcribed in the
nucleus as large RNA precursors called primary microRNAs.44 They are processed in the
nucleus and shuttled to the cytoplasm by the enzymes Drosha, exportin 5, DICER and
argonaute 2. This produces mature double stranded microRNA.45,46 As miRNAs are
normally occurring molecules, they perform several normal functions related to cell
growth, development, and differentiation, but dysregulated expression of these
microRNAs may contribute to tumorigenesis.47 Furthermore, altered expression of
microRNAs in tumor tissue or serum may have a role in the diagnosis of patients with
CRC.48,49 We have previously reported a panel of miRNA that were predictive of
colorectal neoplasia in a large cohort of patients.50
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The miR-200 family is one of the most well defined mediators of EMT, first
reported by 2 separate research groups in 2008.30,31 The miR-200 family is a group of 5
miRNA, that consists of 2 clusters determined by; functional grouping and by genomic
location. miR-200a, miR-200b, and miR-429 are located on chromosome 1p36.33, and
miR-200c and miR-141 are located on chromosome 12p13.31. In contrast, miR-200b,
miR-200c, and miR-429 share the same seed sequence, whereas miR-200a and miR-141
share the same seed sequence for functionality. The seed sequence is the part of the
miRNA that confers specificity to a target mRNA sequence. There is a double-negative
feedback loop between the miR-200 family and ZEB1/ZEB2 expression (Figure 6).31 The
miR-200 family acts to decrease the expression of ZEB1 and ZEB2 through posttranscriptional repression to mediate EMT. In addition, ZEB1 and ZEB2 act on the
promoter region of the miR-200 family to transcriptionally repress miR-200 family
expression. Decreased expression of the miR-200 family leads to a mesenchymal
phenotype to promote EMT.30 TGF-β is a major regulator of EMT, through induction of
ZEB1 and SNAI1 expression, which is also targeted by the miR-200 family to repress
EMT.30,51 However, the miR-200 family has also been shown to induce proliferation
through different signaling pathways such as through a miR-200/RECK/SKP2, CDKN1B
axis and a miR-200/RASSF2/KRAS/ERK1,2 axis.52,53
Multiple clinical studies have demonstrated that tumoral tissue expression of the
miR-200 family is associated with worse clinical outcomes, such as reduced recurrencefree survival54 and overall survival.55 However, there are conflicting individual results
with respect to tissue and serum levels of the miRNA-200 family and these clinical
outcomes.40
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lncRNAs are a recently described class of molecules that have a role in both
normal cellular function and in tumorigenesis. They are another class of non-protein
coding molecules that are defined as being greater than 200 bases in length.56 Similar to
messenger RNA, they are transcribed by RNA polymerase II, but lncRNAs can mediate
their action through a number of different mechanisms. 56,57 Specifically, they have been
described to have been associated with EMT in a number of different cancers and as
lncRNAs have a spectrum of mechanisms of action, they have the potential to be major
regulators of EMT and are the focus of this dissertation.
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Figure 6. Representation of the reciprocal interaction between the miR-200 family and
ZEB1, ZEB2 in EMT.

There is a bidirectional repression between the miR-200 family and the transcription
factors ZEB1 and ZEB2. Both of these factors, in addition to SNAIL1 and SLUG act to
repress E-cadherin, and induce the expression of Vimentin.

O'Brien SJ, Carter JV, Burton JF, Oxford BG, Schmidt MN, Hallion JC, et al. The role of
the miR-200 family in epithelial-mesenchymal transition in colorectal cancer: a
systematic review. International journal of cancer. 2018;142:2501-11.
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CHAPTER III

LONG NON-CODING RNA AND ROLE IN COLORECTAL CANCER

a) Introduction and history of non-coding RNA
In the 1970s, evidence began to emerge to support the hypothesis that a large
proportion of the human genome does not code for protein and was termed junk DNA.
However, investigators began to note that although such DNA does not code for a
protein, that does not mean it does not have a cellular function in some other capacity.58
With the advent of sequencing technology, it is now understood that a large proportion of
the genome is transcribed and warrants investigation to ascertain the function of such
RNAs. There are a large number of non-coding RNAs currently described such as;
ribosomal (r)RNAs, ribozymes, transfer (t)RNAs, small nuclear (sn)RNAs, small
nucleolar (sno)RNAs, and telomere-associated RNAs (TERC, TERRA) microRNAs
(miRNAs), endogenous small interfering (endo-si)RNAs, and Piwi-associated
(pi)RNAs.59
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More recently, long-noncoding RNAs (lncRNA) have been a topical area of
investigation, as they have been shown to have a role in a variety of aspects of normal
cellular function and in disease.60 Some lncRNAs were described prior to the era of RNA
sequencing such as XIST (X-inactive specific transcript).61 XIST was initially described
as having the function of inactivating and transcriptionally silencing one of the X
chromosomes in females. However, it has also been noted that XIST has a major function
beyond this, in other areas of disease.59,62
b) Mechanisms of action of long non-coding RNA
Long non-coding RNA can be classified by their genomic location or by their
molecular function.59 By location, lncRNAs can be classified as; sense, antisense,
intronic, intergenic, or bidirectional in nature (Figure 7).57 By their molecular function,
lncRNA have diverse mechanisms of action (Figure 8)56 which include:
1) Competitive endogenous RNA function - the lncRNA acts as a functional
decoy or “sponge” for other molecules, which prevents these molecules from
executing their function, such as in the case of lncRNA-miRNA sponging;
2) Enhancer function- the lncRNA can act as an enhancer or transcription
factor-like molecule in cells to promote gene expression;
3) Scaffold function- the lncRNA can act to bring proteins spatially close to each
other to aid in ribonuclear protein formation;
4) Guide function- the lncRNA can recruit proteins to a nuclear site such as
recruiting proteins to assist in chromatin remodeling.
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Figure 7. Description of lncRNAs by their genomic locations.

Hermans-Beijnsberger S, van Bilsen M, Schroen B. Long non-coding RNAs in the failing
heart and vasculature. Non-coding RNA Research. 2018;3:118-30.
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Figure 8. Description of lncRNAs by their molecular function

a) Signal mechanism- lncRNA can act to recruit other molecules to an area in the genome
to perform an action. b) Decoy/competitive endogenous RNA mechanism- lncRNA can
act to bind to another molecule which can prevent the target molecule from performing
its action, c) Guide mechanism- lncRNA can bind other molecules and guide them to a
location to perform their function, d) Scaffold mechanism- lncRNA can bind a number of
molecules to bring them close together to perform their function, as in the case of
transcriptional activators, e) Enhancer mechanism- lncRNA can modulate the interaction
between enhancers or promoter regions of genes in chromosomal looping.
Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang CP, et al. Long
noncoding RNAs in cardiac development and ageing. Nature reviews Cardiology.
2015;12:415-25.
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c)

Role of lncRNA in colorectal cancer
lncRNAs have been shown to have a major role in colorectal cancer pathogenesis

in the literature. In particular, lncRNAs have been shown to mediate an effect on EMT
and have a potential role as a biomarker. A review of the literature identified that
lncRNAs act on a number of different signaling cascades; ZEB1,2/ E-cadherin, Vimentin,
Wnt/β-catenin signaling, chromatin remodeling and epigenetic modulation, JAK-STAT3
signaling, mTOR signaling, MAPK/ERK signaling, and TGF-β signaling among others
(Figure 9).

ZEB1,2/ E-cadherin, Vimentin signaling
The ZEB1, 2/E-cadherin, Vimentin axis is a well characterized signaling pathway,
critical to the process of EMT, and a number of different lncRNAs have been shown to
affect this pathway. As previously mentioned, the miR-200 family is a major regulator of
EMT by targeting ZEB1 and ZEB2. A number of the included studies identified lncRNAs
which target the miR-200 family: XIST, N-BLR, and H19, the expression of which are
increased in colon cancer and which are associated with adverse clinical outcomes.63-68 In
addition, N-BLR mediates chemoresistance in vitro, highlighting the potential role of
lncRNA in treatment-resistant colon cancer.65

23

Figure 9. Role of lncRNAs in EMT in colorectal cancer

24
The lncRNAs and their target molecules are organized by signaling pathways via different colors. The lncRNAs are highlighted
indicating a transcriptional factor regulation mechanism, highlighted
highlighted

for a scaffold mechanism.

for a lncRNA/miRNA molecular decoy mechanism, and

Although the miR-200 family is most commonly known to be associated with this
pathway, a number of other studies demonstrate a direct binding with other miRNAs in a
competitive endogenous RNA mechanism. Both SNHG6 and SPRY4-IT1 target miR10169-71, HCP5 targets miR-139,72 while all three subsequently target ZEB1 and directly
mediate EMT. This demonstrates the complexity of manipulating lncRNA in vitro as the
effect on other lncRNA within a pathway has been poorly studied. Similar to these
studies, UICLM targets miR-215, which in turn targets ZEB2 in the signaling cascade.73
Interestingly, B3GALT5-AS1 is a lncRNA which targets the transcription factors ZEB1
and SNAIL through a competitive endogenous RNA mechanism by binding miR-203.74
However, unlike the previously mentioned lncRNA, B3GALT5-AS1 is decreased in
colorectal cancer compared to normal colorectal epithelium. SLUG is another major
regulator of EMT, which activates SNAIL. The lncRNA SNHG15 inhibits the
degradation of SLUG by preventing its ubiquination.75 TWIST1 is another wellcharacterized molecule that regulates EMT. CHRF is an lncRNA that targets TWIST1 by
targeting miR-489.76 These studies demonstrate the different levels at which the ZEB1,
2/E-cadherin, Vimentin axis can be manipulated in vitro. As seen with these studies,
lncRNAs can have a spectrum of different mechanisms and targets, and therefore, indepth analysis of their function on different pathways is essential.

Wnt/β-catenin signaling
The Wnt/β-catenin signaling pathway is another critical mediator of EMT that can
be regulated by lncRNAs. PlncRNA-1 targets β-catenin through a competitive
endogenous RNA mechanism with miR-204 to mediate EMT.77 In contrast, H19 and
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TUG1 target β-catenin indirectly by targeting molecules that interact with β-catenin.66,7880

H19 targets PGRN and TUG1 targets KIAA1199, through miR-29b binding and miR-

600 binding respectively. As previously mentioned, H19 also mediates an effect in the
ZEB1, 2/ E-cadherin, Vimentin signaling pathway, suggesting that lncRNAs can act on
multiple signaling pathways through a competitive endogenous RNA mechanism.
In contrast, CYTOR activates the Wnt/β-catenin signaling pathway by blocking
casein kinase 1-mediated β-catenin phosphorylation.81 Many of the previous studies
demonstrate lncRNAs that bind miRNA in order to mediate their effect, however the
activity of CYTOR is distinct from this mechanism. Similarly, SLC04A1-AS1 stabilizes
β-catenin by preventing β-catenin phosphorylation by glycogen synthase kinase-3, which
leads to a mesenchymal phenotype.82 Both lncTCF7 and CTD903 have been shown to
mediate EMT through Wnt/β-catenin signaling, but further work is required to delineate
the exact mechanism of action.83,84

Chromatin Remodeling and epigenetic modulation
In recent years, epigenetic modification of gene expression through chromatin
remodeling via histone acetylation and methylation has been shown to be a major
mediator of EMT. XIST, MALAT1, and HOXD-AS1 mediate EMT, in part, through
regulation of EZH2.85-88 EZH2 is the enzymatic component of the polycomb repressive
complex 2, which is critical in histone methylation. All three of these lncRNAs mediate
this effect through a competitive endogenous RNA mechanism, by binding different
miRNAs, and are associated with adverse clinical outcomes.63,86,87 Interestingly,
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MALAT1 is increased in expression in chemoresistant cell lines compared to parental
cells, and is associated with reduced recurrence-free survival.87 Modulation of MALAT1
may then be a target for patients with poor chemotherapy response. Similarly, HIF1AAS2 directly binds miR-129, which in turn regulates DNA methylation through
DNMT3A, mediating EMT. DNMT3A is an enzyme that transfers methyl groups to CpG
islands leading to gene repression.89
In contrast to these mechanisms, both TUG1 and SATB2-AS1 regulate EMT
through histone acetylation.78,90 The signaling mechanism for SATB2-AS1 is complex,
whereby SATB2-AS1 acts through a scaffold mechanism to recruit p300 and to acetylate
H3K27 and H3K9 at the promoter region of SATB2. This leads to the subsequent
recruitment of HDAC1 to the promoter of SNAIL by SATB2, thereby silencing SNAIL
and inhibiting epithelial-mesenchymal transition. The mechanism through which TUG1
mediates its effect requires further investigation as it is has not been fully explored.78

JAK-STAT3 signaling
Both BC200 and lncRNA AB073614 act through a transcriptional factor
mechanism to reduce STAT3 phosphorylation in the JAK/STAT signaling cascade.91,92
This leads to the subsequent modulation of matrix metalloproteinases and induces EMT.
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mTOR signaling
The mTOR pathway is a complex signaling family involved in EMT. Both
ZFAS1 and UCA1 induce EMT through a competitive endogenous RNA mechanism but
target different molecules in the pathway.93,94 Through binding with miR-150, ZFAS1
targets VEGFA and subsequently Akt in the mTOR signaling pathway. Few studies
examine upstream regulators of lncRNA and interestingly, the authors demonstrate an
upstream regulator of ZFAS1 through the SP1 transcription factor.93 UCA1 directly
binds miR-143, which targets mTOR to induce EMT. In addition, Jahangiri et al.
demonstrated the complexity of the tumor microenvironment and its effect on lncRNA
expression by co-culturing the cells with cancer-associated fibroblast-conditioned
media.94 This suggests that lncRNA expression can be changed through exogenous
agents.

MAPK/ERK signaling
As previously mentioned, H19 acts through a competitive endogenous RNA
mechanism in both Wnt/β-catenin signaling and in ZEB1, 2/ E-cadherin, and Vimentin
signaling. In addition, H19 also directly binds miR-194, which targets FoxM1.95 FoxM1
is a downstream target in the MAPK/ERK signaling pathway. This suggests that H19
mediates EMT, in part, through a number of different signaling pathways by targeting
different miRNAs. This may suggest its potential use as a therapeutic target. SNHG7 also
affects the MAPK/ERK signaling pathway through a similar mechanism by targeting
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GALNT1 through binding miR-216b in a competitive endogenous RNA mechanism.96
GALNT1 is also a downstream molecule in the MAPK/ERK signaling pathway.97
Three other lncRNAs identified in the search were hypothesized to mediate their
effect on EMT through MAPK/ERK signaling. Both BANCR and NNT-AS1 have
increased expression in colon cancer, whereas SLC25A25-AS1 is decreased in
expression.98-100

TGF-β signaling
The TGF-β signaling superfamily is a complex mediator of EMT. Both PVT1 and
LINC001133 mediate EMT through TGF-β signaling.101,102 Takahasi et al. used a
bioinformatics approach to identify pathways enriched by PVT1 knockdown.101
LINC001133 has a complex role in TGF-β signaling in that it directly binds SRSF-6, an
alternative splicing factor, to mediate EMT. However, SRSF-6 was found to mediate
EMT, independent of LINC001133 expression.

Other signaling pathways:
A number of other studies describe lncRNAs that target different signaling
pathways in order to mediate EMT.
As previously mentioned XIST mediates signaling through the ZEB1, 2/Ecadherin, Vimentin pathway and through chromatin remodeling. However, it also targets
Neuropilin 2 signaling through a competitive endogenous RNA mechanism with miR29

486.103 This study is limited in that it does not explore downstream targets of NRP2
marking it as a potential area of future research as NRP2 is involved in a number of
signaling pathways.104 The study does, however, demonstrate how modulating a single
lncRNA may have multiple effects on different signaling pathways, which suggests that
in-depth investigation of a lncRNA is justified to identify its full role.
CRCMSL also functions through a competitive endogenous RNA -like
mechanism, but it binds HMGB2 in the cellular cytoplasm and prevents its shuttling to
the nucleus. In turn, this prevents the interaction between HMGB2 and OCT4 in the
nucleus, promoting a mesenchymal phenotype.105 This is a different mechanism to the
other included studies that demonstrate that lncRNAs bind miRNAs, and shows the
complexity in studying lncRNAs.
Both lncRNA-ATB and LINC00959 mediate an effect on EMT through caspase
signaling, but lncRNA-ATB is increased in colon cancer, whereas LINC00959 is
decreased in colon cancer compared to normal tissue.106 83 Further work is needed to
identify the exact method through which both of these lncRNAs mediate their effects in
EMT, since caspase signaling is typically associated with apoptosis. FOXD2-AS1 is able
to mediate EMT through NOTCH signaling, but the exact mechanism requires further
investigation.107 As previously mentioned, CYTOR can mediate EMT through
transcriptional regulation of casein kinase 1 in the Wnt/β-catenin signaling pathway, but
it also acts through a scaffold mechanism by mediating the interaction between NCL and
Sam86 in the NF-κB signaling pathway.108 Unlike CYTOR, CPS1-IT1 is decreased in
colon cancer but also acts through a transcriptional factor mechanism.109 CPS1-IT1
induces HIF1-α signaling to mediate EMT, but as those authors note, the hypoxia
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induction model they use likely affects a number of pathways. Since the tumor
microenvironment is a hypoxic environment, this CPS1-IT1 may represent a significant
mediator of EMT.110 Many investigators focus on a single mechanism of action of a
lncRNA, but they may have multiple concurrent mechanisms acting on different
signaling cascades, which highlights the complexity of studying lncRNAs in vitro.
These studies highlight a large number of lncRNAs that are differentially expressed
between colon adenocarcinoma and normal colon epithelium that have a role in colorectal
cancer carcinogenesis, and specifically in the regulation of EMT. A significant number of
the above studies examine lncRNAs in the context of a competitive endogenous RNA
mechanism. As lncRNA have a major role in EMT, this dissertation aims to identify
differentially expressed lncRNAs between colon adenocarcinoma and normal colon
epithelium that target the EMT signaling pathway.

31

CHAPTER IV

ANALYSIS OF AN RNA-SEQUENCING DATABASE TO IDENTIFY
DIFFERENTIALLY EXPRESSED LONG NON-CODING RNAS

a)

Introduction:
As a significant proportion of the human genome is not translated into protein,

there are a large number of potential targets for investigation. In particular, for some
lncRNAs, expression can differ between different cancer types. There is therefore, a need
to characterize the lncRNA expression profile for a specific cancer subtype.111 Some
investigators have shown that lncRNAs can have paradoxical effects in different cancers,
which further underscores the reason for investigation in a particular cancer subtype.111
The identification of differentially expressed lncRNA between colon
adenocarcinoma and normal colon epithelium is important, as this may demonstrate
lncRNAs that may be important in colon cancer carcinogenesis.
The competitive endogenous RNA hypothesis was initially proposed in 2011 by
Salmena et al.112 It was proposed that RNAs could indirectly regulate the expression of
other RNAs, through binding of miRNAs. For example, consider the case where
“miRNA X” binds both “RNA Y” and “RNA Z”. If there is increased expression of
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“RNA Y”, in a pathological case such as in cancer, there is relatively less “miRNA X”
available to bind “RNA Z”, therefore allowing its expression. This is particularly true in
the case of lncRNAs, which have a well-defined function of acting in a competitive
endogenous RNA mechanism, or miRNA sponge mechanism.
The aim of this portion of my work was to identify a number of lncRNAs that are
differentially expressed between colon adenocarcinoma and normal colon epithelium
using an RNA-sequencing data set. We hypothesized that these lncRNAs would have an
interaction with target miRNAs that in turn could be identified using a bioinformatics
tool.

b)

Results:

1) The Cancer Genome Atlas
The Cancer Genome Atlas is a program from the National Institutes of Health in
the United States. The aim of this program was to collect patient clinical and sequencing
data. At present the program has approximately 10,000 patients enrolled, with over 50
cancer types represented. The colorectal adenocarcinoma program was initially published
in 2012 with approximately 300 patients.113 Since then, the program has expanded to
approximately 700 patients. Although this program included both colon and rectal
adenocarcinoma patients from NIH accredited cancer centers, none of the rectal
adenocarcinoma patients received neoadjuvant chemoradiotherapy, which is a common
clinical practice per the National Comprehensive Cancer Network Guidelines.9 These
patients were therefore excluded from further analysis.
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2) RNA sequencing data download and processing
An application was made to the National Institute of Health Data Access
Committee to obtain access to the raw sequencing data for the colon adenocarcinoma
program. Patients with colon adenocarcinoma were identified from the Genomic Data
Commons portal (https://portal.gdc.cancer.gov/). The raw sequencing data set was
downloaded on February 21st 2018 to the University of Louisville computer cluster,
where it was encrypted until further use.
Dr. Theodore Kalbflesich performed the data download and aligned the raw
sequencing data to the most up-to-date human genome, using the ENSEMBL gene
identifying codes (https://useast.ensembl.org/index.html).

3)

Clinical data set download
The associated clinical data set was downloaded using FirebrowseR

(https://github.com/mariodeng/FirebrowseR). This data set was cross-verified using
cBioPortal for Cancer (https://www.cbioportal.org/).114,115 Patient demographics
included; age at diagnosis, gender, race, and body mass index (BMI). Cancer specific
details included; American Joint Commission on Cancer stage116, microsatellite
instability status, lymphatic invasion, venous invasion, and preoperative serum
carcinoembryonic antigen. None of the patients received neoadjuvant chemotherapy or
radiotherapy
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4)

Differential Gene Expression between paired colon adenocarcinoma and normal

colon epithelium
Using the clinical data as a means of identifying appropriate patients for
comparison, we identified 40 patients with colon adenocarcinoma who also had an RNAsequencing data file for adjacent normal colon epithelium. The baseline demographic
data of these 40 patients are described in Table 2. Dr. Sudhir Srivastava performed a
differential gene expression comparison between the paired colon adenocarcinoma and
normal colon epithelium data. There was a distinct differential clustering of the colon
adenocarcinoma samples compared to the normal colon epithelium samples, as
demonstrated by a multidimensional scaling plot (Figure 10).
The pipeline for identifying a number of differentially expressed lncRNAs is
described in Figure 11. Some 33,514 transcripts were identified from a comparative
analysis of all transcripts, of which 9,853 were non-coding. Using the cut-offs of a log
fold change of greater than 1.5 or less than 1.5, and a false discovery rate of 0.05, we
identified 348 differentially expressed non-coding RNAs. Of these non-coding RNAs,
120 were increased in expression in cancer compared to normal epithelium, and 228 were
decreased in expression.
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5) Validation of differentially expressed non-coding RNAs in the colon adenocarcinoma
cohort
The expression values of 70 of the most differentially expressed lncRNAs, along
with 10 housekeeper genes, were confirmed using all of the available colon
adenocarcinoma patients from The Cancer Genome Atlas. A similar differential gene
expression analysis was performed by Dr. Sudhir Srivastava to confirm that these genes
remained significantly differentially expressed when the sample size was increased.

6) Selection of candidate molecules- manually curated for criteria
From these two comparative analyses, a number of selection criteria were used to
identify candidate lncRNAs for further investigation. All of the lncRNAs were confirmed
to be increased in expression in colon adenocarcinoma compared to normal colon
epithelium. In addition, because a large number of non-coding RNAs may not have an in
vitro effect, we sought to investigate lncRNAs which have been described to have a
cellular function in the literature, through a PubMed and EMBASE search.
Each lncRNA was entered to the bioinformatics prediction program DIANAlncBASE v2.0.117 This is a bioinformatics tool that allows for the identification of both
predicted and experimentally validated lncRNA-miRNA direct binding interactions. The
ENSEMBL gene ID of each lncRNA was entered into the program and the
experimentally validated target miRNAs were generated for each lncRNA.
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Table 2. Demographics and tumor details of colon adenocarcinoma patients with both a
colon adenocarcinoma sample and normal adjacent colon epithelium sample
N=40
N
(%)
74 (64-81)

Variable
Age at diagnosis (median, IQR)
Gender
Male
Female

20 (50)
20 (50)

Race
Caucasian
African American
Data not available
Height (cm)(median, IQR)
Weight (kg) (median, IQR)
2

Body Mass Index (kg/m ) (median, IQR)
Pre-operative CEA (ng/mL) (median, IQR)
Tumor location
Cecum
Ascending colon
Hepatic flexure
Transverse colon
Splenic flexure
Descending colon
Sigmoid colon
Tumor Stage
Stage 1
Stage 2
Stage 3
Stage 4
Microsatellite Status
Microsatellite Stable
Microsatellite Instable- Low
Microsatellite Instable- High
Data not available
Lymphatic Invasion
Yes
No
Data not available
Venous Invasion
Yes
No
Data not available
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22 (55)
4 (10)
14 (35)
169 (161-180)
74 (63-95)
26.2 (23.3-32.1)
4.3 (1.6-18.4)
7(18)
11(29)
3(8)
1(3)
2(5)
1(3)
13(34)
4(10)
22(54)
7(18)
7(18)
24 (60)
6 (15)
8 (20)
2 (5)
13(32)
23(58)
4(10)
7(18)
29(72)
4(10)

Figure 10. Multidimensional Scaling plot demonstrating differential clustering of colon adenocarcinoma samples compared to normal
colon epithelium samples.
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Figure 11. Schematic of candidate lncRNAs identified from exploratory differential gene expression analysis between colon
adenocarcinoma and paired normal adjacent colon epithelium.
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Finally, the expression of these lncRNAs was verified to be present in colon
adenocarcinoma cell lines by using the Cancer Cell Line Encyclopedia.118 This resource
from the Broad Institute and the Massachusetts Institute of Technology, has RNAsequencing data on over 1000 cell lines and allows investigators to ensure that a given
cell line expressed a certain RNA. This allowed us to select three colon adenocarcinoma
cell lines with robust expression of the lncRNAs. This selection process yielded seven
candidate lncRNAs for further investigation (Table 3).
Following our initial comparative analysis, six of the seven lncRNAs had
persistently increased expression in colon adenocarcinoma compared to normal colon
epithelium. FAM83H-AS1 expression data was not available on Firebrowse. The Cancer
Cell Line Encyclopedia was used to compare the expression of each of the lncRNAs in
each cell line. ZFAS1 and GAS5 had the most consistent and robust expression across
our three cell lines, SW480 (Stage II/ Duke’s B colon adenocarcinoma), HT29 (Stage III/
Duke’s C colon adenocarcinoma), and Caco2 (Stage unknown/ Duke’s stage unknown),
but there was heterogeneity of expression among the others. H19, PVT1, and GAS5 were
the most commonly investigated lncRNAs, yielding the highest number of papers
investigating the lncRNA from our literature search. There were 20 miRNA confirmed
targets of PVT1, 33 miRNA targets for UCA1, 28 miRNA targets for H19, 5 miRNA
targets of FER1L4, 18 miRNA targets for GAS5, and 5 miRNA targets for ZFAS1. There
were no confirmed miRNA targets for the lncRNA FAM83H-AS1. The interactions for
each of these lncRNAs are shown in figure 12a-f.
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Table 3. Characteristics of each of the seven lncRNAs across the different criteria used to identify candidate molecules for further investigation in
vitro.

lncRNA

TGCA Analysis
FirebrowseR
Number of
Cancer Cell line
Colon
Colon
Papers
Encyclopedia
adenocarcinoma
False
adenocarcinoma
Number
Reporter
DIANA
Expression log2 (FPKM)
vs. paired
Discovery
(N=458) vs.
Number
of
assay
lncBASE
Normal
Rate
Normal
of Papers
Papers
confirmed (Experimental
Epithelium
(adjusted
Epithelium
SW480 HT29 CACO2 (PubMed) specific
lncRNAvalidation)
n=40
p-value)
(n=41)
lncRNA(Stage (Stage
(Stage
miRNA
(log fold
(Log Fold
miRNA
II)
III)
N/A)
interaction
change)
Change)
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FAM83HAS1

2.42

1.37E-41

Not available

-0.09

4.12

3.42

10

0

0

48

PVT1

2.37

2.99E-41

7.70

1.68

3.49

0.87

1129

41

20

21

UCA1

2.30

3.54E-10

7.54

1.35

1.50

5.61

198

53

33

2

H19

2.05

1.11E-7

4.14

-1.81

-0.79

2.45

2467

198

28

172

FER1L4

2.89

1.89E-14

6.15

-3.56

4.95

-1.78

122

4

5

5

GAS5

1.14

4.02E-14

2.29

6.96

6.71

6.34

233

39

18

199

ZFAS1

1.51

6.87E-24

3.20

8.12

6.85

8.06

50

10

5

162

FPKM- Fragments Per Kilobase of transcript per Million mapped reads, N/A- Not available

Figure 12. Confirmed miRNA that target each of the 7 selected lncRNA, identified
through both bioinformatics prediction and literature reporting positive lncRNA-miRNA
direct binding, a) PVT1 Targets, b) UCA1 targets, c) H19 targets, d) FER1L4 targets, e)
GAS5 targets, f) ZFAS1 targets.

Modified from DIANA lncBASE v2. Paraskevopoulou MD, Vlachos IS, Karagkouni D,
Georgakilas G, Kanellos I, Vergoulis T, et al. DIANA-LncBase v2: indexing microRNA
targets on non-coding transcripts. Nucleic acids research. 2016;44:D231-D8.
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d) Discussion
This chapter describes a path to discover a number of differentially expressed
RNAs and lncRNAs from an RNA-sequencing data set. By comparing patients with both
a colon adenocarcinoma and a normal adjacent colon epithelium RNA-sequencing data
file, we identified a large number of differentially expressed RNAs. After confirmation of
differential expression in the entire cohort of patients with colon adenocarcinoma
(N=441), we selected seven lncRNAs for further investigation on the basis of a number
of criteria.
By integrating The Cancer Genome Atlas and the Cancer Cell Line Encyclopedia,
it allows investigators to select differentially expressed RNA in clinical samples and to
select appropriate cell lines for investigation on the basis of their target lncRNA and other
RNA expression. Historically non-coding RNAs were thought to not have a function, but
through different bioinformatics approaches they are now recognized to have a major
function in normal cellular signaling and in cancer signaling.119
We have identified a number of experimentally verified miRNA targets for each
lncRNA with the exception of FAM83H-AS1. These interactions are from both highthroughput sequencing interactions and with luciferase reporter assay-based techniques.
Interestingly, the miR-200 family appears to target ZFAS1, H19, and PVT1, which is a
major regulator of epithelial-mesenchymal transition in cancer.40 In addition, both GAS5
and PVT1 directly target miR-203 which is another regulator of epithelial-mesenchymal
transition in cancer.120
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A number of investigators combine colon adenocarcinoma and rectal
adenocarcinoma together when using The Cancer Genome Atlas, but there are significant
molecular and clinical differences between these two types of large bowel cancer. Rightsided colon adenocarcinomas are more likely to be high microsatellite instable tumors,
whereas left-sided colon adenocarcinomas are more likely to be chromosomal instable
tumors. 20 BRAF mutations more commonly occur in colon adenocarcinomas, and rectal
adenocarcinomas typically have APC and TP53 mutations. 21 Clinically, rectal cancer has
a tendency towards pulmonary metastases, whereas colon cancer tends to develop liver
metastases. 121,122 Typical adjuvant chemotherapy strategies for colon cancer include
fluorouracil-based therapies.22,123 Finally, as previously mentioned, none of the patients
in the rectal adenocarcinoma cohort received preoperative neoadjuvant
chemoradiotherapy, a current standard of care for locally advanced cancers.113 We
therefore restricted our use of The Cancer Genome Atlas to patients with colon
adenocarcinoma.
In the previous chapter, we described a large number of lncRNAs that are
differentially expressed in colon adenocarcinoma compared to normal colon epithelium
and that have a role in EMT from the literature. Using a methodical approach to identify
highly differentially expressed lncRNAs between colon adenocarcinoma and normal
colon epithelium, we selected seven lncRNAs with experimentally validated miRNA
targets for further investigation.
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CHAPTER V

HYPOTHESIS, SPECIFIC AIMS, AND EXPERIMENTAL PLAN

a)

Key Objective
To identify differentially expressed lncRNAs in colon adenocarcinoma compared

to normal adjacent colon epithelium from an exploratory RNA-sequencing analysis, and
to validate their expression in clinical samples. To furthermore characterize the
mechanism of action and phenotypic function of selected lncRNAs in colon
adenocarcinoma cell lines.

b)

Hypothesis
We hypothesize that ZFAS1, a lncRNA identified from an exploratory

comparative RNA-sequencing analysis, can modulate the behavior of three colon cancer
cell lines in vitro.
The interrogation of RNA-sequencing data sets allows a transcriptome-wide
analysis of RNAs between colon adenocarcinoma samples and normal colon epithelium.
Using these data, differentially expressed lncRNAs can be identified for investigation in
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colon adenocarcinoma cell lines. ZFAS1 is a well-characterized lncRNA that has been
shown to promote tumor progression in different cancers. However, its role in colorectal
cancer has not been fully elucidated specifically regarding its mechanism or effect on
colon cancer cell line phenotype.

c)

Specific Aims
1) To validate the expression of differentially expressed lncRNAs identified from

a RNA-seq comparison between paired colon adenocarcinoma and normal adjacent colon
epithelium, in clinical samples from the University of Louisville tissue biorepository.
2) To investigate the effect of lncRNA ZFAS1 knockdown on target miRNA
expression as well as the effect of transfection with miRNA mimics on lncRNA
expression.
3) To demonstrate the effect of lncRNA knockdown on colon cancer cell line
phenotype, specifically focusing on ZFAS1 and the signaling pathway through which it
mediates EMT.

d)

Experimental Plan
The overall goal of this project is to identify differentially expressed lncRNAs in

an RNA-seq database, and then to investigate how the selected lncRNAs modulate colon
cancer cell line behavior in vitro. We will in turn validate the results of the RNAsequencing data set in patient samples from the University of Louisville tissue
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biorepository. The effect of lncRNA knockdown on target miRNAs will be examined
with a specific focus on ZFAS1. To further define this, miRNA mimics will be
transfected to investigate for a reciprocal change in lncRNA expression. This will direct
further investigation into a target signaling pathway and into the role of the lncRNA on
cellular phenotype. The role of ZFAS1 on the EMT signaling cascade, the ZEB1/ Ecadherin, Vimentin signaling pathway will be examined in detail as shown in Figure 13.
Each of these specific elements will be addressed in the remaining chapters.
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Figure 13. Hypothesis overview- The lncRNA ZFAS1 which was identified to be differentially expressed from the exploratory RNAseq analysis, will have an association with tumor progression via miR-200/ZEB1/E-Cadherin, vimentin signaling
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CHAPTER VI

MATERIAL AND METHODS

a.

Ethics Statement:
The experiments in this study were approved by the institutional review board at

the University of Louisville. (IRB: 97.0361)

b.

The Cancer Genome Atlas:

1. RNA-sequencing data
The Cancer Genome Atlas is a program from the National Institutes of Health,
which contains clinical and sequencing data for over 10,000 patients from 68 different
primary sites. There are different tiers of access to the data. An application to obtain
access to the restricted tier of raw sequencing data was made to the National Center for
Biotechnology Information, which contains the original sequencing data files. This
application was made and approved through
https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login. The sequence data for patients
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with colon adenocarcinoma were downloaded to the University of Louisville computer
cluster and stored with an encryption to the standard of the National Institutes of Health.

2. RNA-sequencing data alignment and statistical analysis
The data for all patients was aligned by Dr. Theodore Kalbfleisch using STAR
(Spliced Transcripts alignment to a Reference). This analyzed data was annotated to the
known ENSEMBL identifier codes (https://www.ensembl.org/index.html). For an initial
comparative analysis, all patients with both a colon adenocarcinoma RNA-seq data file
and a normal adjacent colon epithelium RNA-seq data file were selected. A comparative
analysis of these patients was conducted by Sudhir Srivastava, using a binomial
regression model, to provide a fold change and adjusted p-value (false discovery rate) for
each gene.
The normalized gene expression for ZFAS1, its target microRNAs, and target
messenger RNAs were downloaded using cBioPortal for Cancer Genomics
(https://www.cbioportal.org/).115,124 The expression format of ZFAS1 and its target
mRNAs was in the format of RSEM (Reads Per Kilobase Per Million Mapped Reads).125
The format of the miRNA data is in RPM (Reads Per Million miRNA Precursor Reads).
These are standard formats for comparison on cBioPortal.
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3. Clinical data set
The clinical data set for the colon adenocarcinoma patients from The Cancer
Genome Atlas was downloaded using FirebrowseR
(https://github.com/mariodeng/FirebrowseR) and using R Studio (Rstudio Inc, Boston
MA). The validity of the clinical data was verified by downloading the clinical data from
cBioPortal for Cancer Genomics (https://www.cbioportal.org/).

c.

Human Samples:
1. Human Whole Tissue RNA Extraction
Prior to and during the process of RNA extraction, RNase Zap (Ambion, USA)

was used on workspace surfaces and tools to prevent tissue RNA degradation. The
Qiagen miRNeasy® extraction kit (Qiagen, Hilden, Germany) and protocol were used for
extraction. Six tubes from the kit were labeled with a sample identifier: four 1.5 mL
tubes, one Qiashredder column (Qiagen, Hilden, Germany), and one micro filter column.
A container of ice was used to maintain low temperatures while working with fresh
tissue. Plastic petri dishes were cleaned with 70% ethanol and sprayed with RNase Zap
before use. A scale was used to measure the mass of the tissue cut.
The tissue of interest was taken from the freezer, placed on ice, then cut and its
mass recorded. Once all the tissue was cut, it was minced with a sterile scalpel into a gel
consistency. The desired tissue mass was between 15-30 mg. The minced tissue was then
placed into a tube with 700 μL of QIAzol lysis reagent (QIAGEN, miRNeasy kit, Hilden,
Germany) and incubated for 5 minutes at room temperature. The homogenate was added
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to the shredder column and centrifuged for 2 minutes at 17,000 x g. The shredder was
removed from the collection tube and placed in a 1.5mL tube containing 140 μL of
chloroform. The tube was vortexed for 15 seconds before being centrifuged at 12,000 x g
for 15 minutes. The top layer of the aqueous solution was extracted, without disturbing
the interface between the top and bottom layers. A volume of 100% ethanol was mixed
with this extracted layer, equaling one and a half times the volume of the extracted layer.
700 μL of the sample was pipetted into a QIAgen filter column and centrifuged at
8,000 x g for 15 seconds, after which the effluent was discarded. The filter column then
underwent a series of washes using propriety solutions within the kit beginning with 700
μL of RWT solution followed by 500 μL of RPE solution. Both washes occurred at 8,000
x g for 15 seconds, with the effluent being discarded. Another 500 μL of RPE solution
was added and centrifuged at 8,000 x g for 2 minutes. The filter column was then
transferred into a new 1.5 mL collection tube, and 30 μL of RNase-free water (QIAGEN
miRNeasy kit, Hilden, Germany) was pipetted directly onto the filter. The tube was then
centrifuged for 1 minute at 8,000 x g to elute the miRNA. Samples were stored at -80C.

2. Human Whole Tissue Protein Extraction
Frozen whole colon adenocarcinoma tissue and matched normal adjacent tissue
samples were obtained from the University of Louisville Surgical Biorepository. Normal
adjacent tissue was excised 10 cm away from the tumor site. Macrodissection of the
tissue produced 20 to 50 mg pieces -which were used for protein extraction using
hematoxylin and eosin stained slides as a guide. Tissue was homogenized on ice using a
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Tissue Tearor (Biospec Products, Inc., Bartlesville, OK) in 300 μL of
radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich, St. Louis, MO)
supplemented with 0.1% protease inhibitor and 0.1% phosphatase inhibitor (Thermo
Fisher Scientific, Waltham, MA). Tissue samples were sonicated with a Sonifier 250
(Branson Ultrasonics, Danbury, CT) and transferred into 1.5 mL microcentrifuge tubes.
The tubes were then centrifuged at 11,000g for 10 minutes. Pelleted debris was discarded,
and the supernatant extracted and stored at -80°C until needed. Total protein
concentrations were quantified using a bicinchoninic acid (BCA) protein quantification
assay (Thermo Fisher Scientific, Waltham, MA). Samples were measured in duplicate.
BCA assay plates were read on a SPECTRAmax PLUS spectrophotometer (Molecular
Devices, San Jose, CA) at 540 nm.

d.

Laser Capture Microdissection:
1. Human Tissue Acquisition and Sectioning
Fresh frozen samples of malignant colon adenocarcinoma and normal adjacent

colon epithelium from 24 patients were obtained from the University of Louisville
Surgical Biorepository. The normal tissue sample was taken 10cm from the tumor site.
Tissue sections from these samples were cut at 7µm thickness and mounted on negatively
charged slides from the Histogene™ LCM Frozen Section Staining Kit (Thermo Fisher
Scientific, Waltham, MA) by the University of Louisville, Department of Pathology.
One slide per tissue sample was stained using hematoxylin and eosin for reference. Other
tissue sections were frozen and stored at -20C until staining.
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2. Staining of Fresh Tissue Sections
The protocol from Applied Biosystems Arcturus Staining Kit (Thermo Fisher
Scientific, Bedford, MA) was followed. One slide at a time was stained and dehydrated
for each Laser Capture Microdissection session. The protocol was implemented using
seven plastic Coplin tubes, prefilled with dehydrating solutions: 25 mL 75% ethanol
(tube #1 & 4), 25 mL distilled water (tubes #2 & 3), 25 mL 95% ethanol (tube #5), 25 mL
100% ethanol (tube #6), 25 mL xylene (tube #7). Each slide was dipped into tubes 1-2
sequentially for 30 seconds, then placed flat on an RNase free surface and stained with
Histogene™ staining solution for 20 seconds. The stain was drained from the slide using
a Kimwipe (VWR, Radnor, PA) and then placed into tubes 3-6 sequentially for 30
seconds each and into tube 7 for 5 minutes. The slide was then placed horizontally on an
RNase free surface and air dried for 5 minutes.

3.. Laser Capture Microdissection
Immediately following slide staining, normal epithelium or tumor tissue was
identified by light microscopy at 4x and 10x magnification using the H&E slide as a
reference. Tissue of interest from the stained slide was then laser captured at 10x
magnification onto CapSure Macro LCM Caps (Thermo Fisher Scientific, Waltham,
MA) using the ArcturusXT™ Laser Capture Microdissection System. After laser capture,
caps were placed onto a microcentrifuge tube, containing 50μL of extraction buffer from
the PicoPure™ RNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA) and
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inverted so that the buffer came into contact with the tissue on the cap. The tubes were
then incubated at 42C for 30 minutes. After incubation the tubes were centrifuged at 800
x g for 2 minutes and stored at -80C.

4. RNA extraction
Isolation of total RNA was performed using the Arcturus PicoPure™ RNA
Isolation Kit (Thermo Fisher Scientific, Baltics UAB) and protocol. Microcentrifuge
tubes with cell extract from the LCM were thawed. 70% ethanol was added to each
centrifuge tube so that the cell extract to 70% ethanol ratio was 1:1. RNA purification
columns were pre-conditioned with 250 μL conditioning buffer, incubated for 5 minutes
at room temperature, and centrifuged in the provided collections tubes at 16,000 x g for 1
minute. After conditioning, 100 μL cell extract and ethanol mix were pipetted into the
RNA purification column. The columns were centrifuged for 2 minutes at 100 x g, and
then at 16,000 x g for 30 seconds. Effluent was removed from the collection tube. The
tube then underwent a series of washes using 100 μL of wash buffer 1, followed by 100
μL of wash buffer 2. Both washes were centrifuged for 1 minute at 8,000 x g. Effluent
was discarded between each spin. The purification column was transferred to a new 0.5
mL microcentrifuge tube, and 20 μL elution buffer was pipetted directly onto the
membrane of the column. The tube was incubated 1 minute at room temperature and
centrifuged 1 minute at 1,000 x g, followed by 1-minute centrifugation at 16,000 x g to
elute the RNA. Samples were stored at -80C until further use.
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e.

Cell lines:
The Cancer Cell Line Encyclopedia (https://portals.broadinstitute.org/ccle) is a

Broad Institute (Boston, MA) database that contains RNA-seq expression data from
common cancer cell lines. This facilitates selection of cell lines expressing RNAs of
interest. After consulting this database, the HT-29 (ATCC® HTB-38™; Stage III), SW480 (ATCC® CCL-228™; Stage II), and Caco2 (ATCC® HTB-37™; Stage unknown)
colon adenocarcinoma cell lines were purchased from the American Type Culture
Collection (Manassas, VA). The morphology of each cell line as examined by light
microscopy is shown in Figure 14-16. Gene mutations and the consensus molecular
subtype of each cell line are described in Table 4.126
i. HT-29 (ATCC® HTB-38™)
The HT-29 cell line is derived from a 44-year-old woman with a stage III (Duke’s
C) colon adenocarcinoma. As per the guidelines from American Type Culture Collection
(ATCC), these cells were grown in McCoy’s 5A medium, supplemented with 10% fetal
bovine serum (FBS), 1% penicillin, streptomycin, amphotericin B, and 1% L-glutamine.
HT-29 cells have a more epithelial phenotype and are more locally proliferative than
invasive.
ii. SW-480 (ATCC® CCL-228™)
The SW-480 cell line is derived from a 50-year-old man with a stage II (Duke’s
B) colon adenocarcinoma. The SW-480 cell line was maintained in RPMI-1640 medium,
supplemented with 10% FBS, 1% penicillin, streptomycin, amphotericin B, and 1% L-
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glutamine, as per ATCC guidelines. SW-480 cells have a mesenchymal phenotype and
have a more invasive phenotype rather than a locally proliferative phenotype.
iii. Caco2 (ATCC® HTB-37™)
The Caco-2 cell line cells were grown in Eagle's Minimum Essential Medium
(EMEM), supplemented with 10% FBS, 1% penicillin, streptomycin, amphotericin B,
and 1% L-glutamine, as per ATCC recommendations. Caco-2 cells have a mesenchymal
phenotype, and have a more invasive phenotype with slow proliferation.
All cell lines were cultured in 75cm3 or 125cm3 cell culture flasks (Corning Inc.,
Corning, NY) and incubated at 37°C and 5% CO2. Cell lines were authenticated using
Short Tandem Repeat profiling (ATCC Cell Line Authentication service, Manassas VA).
This was performed every 6 months.
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Figure 14. Morphology of the HT-29 cell line (Stage III) as examined with light
microscopy at low and high density viewing.

At low confluency, the HT-29 cells grow individually and appear rounded. At
higher confluency, the cells grow in aggregated patches to assume a sheet-like
appearance.

HT-29 ATCC® HTB-38™ details are available at
https://www.atcc.org/products/all/HTB-38.aspx#generalinformation
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Figure 15. Morphology of the SW-480 cell line (Stage II) as examined with light
microscopy at low and high-density viewing.

At low cell density the SW-480 cell line grows in singular rounded cells, but at a
higher confluency, the SW480 cells take on a more polygonal shape. The cells may also
take on a tethered appearance at higher confluency.

SW-480 (ATCC® CCL-228™) details are available at:
https://www.atcc.org/products/all/CCL-228.aspx#characteristics
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Figure 16. Morphology of the Caco-2 cell line (Unknown Stage) as examined with light
microscopy at low and high density viewing.

At low cell density the Caco-2 cells have a heterogeneous appearance in that the
cells grow as single cells or in clumps, but also can have variation in individual cell size.
At a higher confluency, the Caco-2 cells grow with a sheet-like appearance and can
demonstrate differences in individual cell size.

Caco2 (ATCC® HTB-37™) details are available at:
https://www.atcc.org/products/all/HTB-37.aspx#characteristics
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Table 4. Gene mutations and molecular characteristics of the 3 cell lines used for
in vitro studies.126

Gene Mutations

Molecular Characteristics

Cell line

Microsatellite
TP53

KRAS

BRAF

PIK3CA

PTEN

CIMP

CMS

Instability
HT-29

p.V600E;
p.R273H

wt

(Stage III)

wt

wt

MSS

CIMP+

3

p.T119Sc

SW-480

p.R273H;

(Stage II)

p.P309S

p.G12V

wt

wt

wt

MSS

CIMP-

4

wt

wt

wt

wt

MSS

CIMP-

4

Caco-2 (Stage
p.E204X
unknown)

TP53- Tumor Protein 53 gene, KRAS- Kirstin Rat Sarcoma gene, BRAF- B
rapidly accelerated fibrosarcoma gene, PIK3CA- Phosphatidylinositol 3-kinase gene,
PTEN- Phosphatase and tensin homolog gene, CIMP- CpG island methylator phenotype,
CMS- Consensus molecular subtype, wt- wild type, MSS- microsatellite stability stable.
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f.

Small interfering RNA (siRNA)
Five small interfering RNAs (siRNA) were purchased from DharmaconTM

(Horizon Inspired Cell Solutions, Lafayette, CO). The LincodeTM siRNAs were as
follows: Human GAS5 Control (Reference: D-001310-10-05), Non-targeting siRNA
(Reference: D-001320-10-05), Human PVT1 (Reference: R-029357-00-0005), Human
ZNFX1-AS1 (Reference: RU-034485-00-0005), and Human GAS5 (Reference: R188293-00-0005). Each siRNA was delivered as a dry pellet. A 5X siRNA buffer
[DharmaconTM (Horizon Inspired Cell Solutions, Lafayette, CO)] was diluted to a 1X
concentration with RNase free water. This 1X siRNA buffer was then used to resuspend
siRNA pellets to 5 μM solutions as recommended by the manufacturer. Once
resuspended, solutions were placed on an orbital shaker for 30 minutes at room
temperature and then centrifuged. The concentration of each solution was confirmed to
be 5 μM using a NanoDrop® 2000 spectrophotometer (ThermoFisher ScientificTM,
Waltham, MA, USA). Resuspended siRNAs were aliquoted per the manufacturer’s
recommended amounts and stored at -20°C.
HT-29, SW-480, and Caco2 cells were seeded in 6-well plates at 1.66 x 105 cells
per well and allowed to grow to confluence for 24 hours in Antibiotic/Antimycotic (A/A)
free media. Following manufacturer’s instructions for transfection, 5 μM siRNA was
diluted with serum-free media, and further combined with a DharmaFECT reagent (x mL
DharmaFECT solution and x mL serum-free media). After removing the original media,
the combined transfection reagents were added to each respective well of the 6-well plate
and diluted with A/A free media. Transfection was subsequently performed for 24-hours
at 37oC in 5% CO2, after which the solution in each well was removed and replaced with
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2 mL of A/A free media. Cells were then further incubated for downstream experiments
at variable time points depending on the experiment.

g.

RNA extraction
i. Protein and RNA Isolation SystemTM (PARIS) Kit (Life Technologies®, Carlsbad

CA).
Cells from culture were placed in a 15mL conical tube, and pelleted at a speed of
113 x g or 7 minutes using an Eppendorf Centrifuge 5804 R (Eppendorf AG, Hamburg,
Germany). The supernatant was removed, and the cells resuspended in 1 mL cold
Phosphate Buffer Saline (PBS). The resuspension was transferred to a 1.5 mL
microcentrifuge tube, and pelleted at 500 x g for 1 minute using an AccuSpin Micro 17
microcentrifuge (Fisher Scientific, Hampton, NH).
The Protein and RNA Isolation System (PARIS) kit (Life Technologies®,
Carlsbad CA) was used to separate the nuclear fraction of RNA from the cytoplasmic
fraction. Samples of cells were resuspended with 300 μL ice-cold Cell Fractionation
Buffer. The pellet was gently resuspended by carefully pipetting up and down 3-4 times
to prevent contamination of the cytoplasmic fraction with nuclear components. Once the
mixture was homogenized, cells were incubated on ice for 5-10 minutes. After
incubation, the cells were centrifuged at 500 x g for 5 minutes at 4°C in order to separate
the mixture into nuclear (pellet) and cytoplasmic (supernatant) fractions. The supernatant
was carefully collected, placed into a new microcentrifuge tube, and stored on ice until
further use. The pellet was then washed with ice-cold Fractionation Buffer and
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centrifuged at 500 x g for 1 minute at 4°C in order to ensure that there was little
contamination between the fractions. Next, the supernatant was removed and discarded.
The nuclear pellet was resuspended in 300 uL ice-cold Cell Disruption Buffer by
vigorously pipetting to ensure lysis and homogenization. The nuclear fraction was then
placed on ice until further use.
To begin RNA Isolation, 300 μL 2X Lysis/Binding Solution was added to the
total, nuclear and cytoplasmic fractions. Next, an equal amount of 100% ACS grade
ethanol was added to each fraction. The samples were then pipetted into the supplied
filter cartridges/collection tubes, and centrifuged at 15,000 x g for 1 minute. The effluent
was discarded, and then 700 μL Wash Solution 1 added to each sample. The tubes were
then centrifuged at 15,000 x g for 1 minute. The effluent was discarded, and 500 μL
Wash Solution 2/3 was added. The sample was once again centrifuged at the same
parameters as previously. This previous step is then repeated, with another 500 μL Wash
Solution 2/3 being added to the tubes. Next, the filter cartridges were added to new tubes,
and 30 μL Elution Solution heated to 95°C was added to each tube. Samples were then
centrifuged at 15,000 x g for 30 seconds. Another 30 uL Elution Solution was applied to
the filter, and samples centrifuged at 15,000 x g for 30 seconds. The filter cartridges were
discarded, and the concentration and purity of the isolated RNA obtained using
NanoDrop® 2000 spectrophotometry. Samples were stored at -80°C until further use.
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ii. Qiagen miRNeasy Mini Kit (Qiagen, Hilden, Germany)
The media from one well in a 6-well plate was removed without disrupting the
layer of cells. The cells were lysed using 700 μL Qiazol Lysis Reagent (Qiagen, Hilden,
Germany). The solution was then stored at -80oC for further RNA processing. Total RNA
extraction was performed using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Six
hundred μL Chloroform (Sigma Aldrich) was added to the lysis solution, vortexed, and
centrifuged at 12,000 x g for 15 minutes. The top, clear aqueous phase was transferred to
a new tube and washed with 100% ethanol, followed by centrifugation at 8,000 x g for 15
seconds. A series of washes was then completed following the manufacturer’s protocol,
discarding the effluent after each successive wash. Total RNA was then eluted with 30
μL nuclease-free H2O and centrifuged at 8,000 x g for 1 minute. Total RNA
concentration and purity were assessed using Nanodrop® 2000 spectrophotometry
(Thermo Fisher Scientific, Waltham, MA). Total RNA was considered pure and usable if
the sample had a 260/280 ratio of 1.8-2.2. Samples were stored at -80oC until further use.

h.

Reverse Transcriptase and Quantitative Real-time Polymerase Chain
Reaction (RT qRT-PCR)
i. Superscript™ IV VILO™ mRNA RT qRT-PCR
For mRNA or lncRNA single assay quantification, the extracted template RNA

was converted to cDNA using a Superscript™ IV VILO™ Master Mix with ezDNase
enzymes (Life Technologies, Carlsbad, CA). The reverse transcription (RT) total reaction
volume for each sample was 20μL, consisting of the following components:
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Component

Volume per 20 𝝁L reaction (𝝁L)

Superscript™ IV VILO™ Master Mix

4.0

Template RNA

1.0

Nuclease Free H2O

15.0

Total

20.0

After the master mix was made, it was gently mixed with the template RNA of
each sample in a 96-well reaction plate. The reaction plate was promptly sealed,
vortexed, and centrifuged prior to running RT on a pre-set thermal cycler program. Upon
completion, the cDNA was used either used immediately to perform qRT-PCR or stored
until further use at 4oC.
Nucleic acid quantification for RNA targets was performed using a Step-One Plus
qRT-PCR system (Life Technologies, Carlsbad, CA). Each reaction was performed in
duplicate at a 10μL qRT-PCR reaction volume. A master mix solution for qRT-PCR for
each lncRNA was made as follows:

Component

Volume per 10 𝝁L reaction (𝝁L)

20x TaqMan Gene expression assay

0.5

TaqMan Fast Advanced Master Mix

5.0

Nuclease Free H2O

3.5

Total

9.0

The following 20x TaqMan Gene Expression Assay primers were selected for
use:
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ZFAS1 (Hs01379985 M1)

H19 (HS00399294_g1)

GAS5 (Hs03464472_m1)

ZEB1 (Hs01566408_m1)

PVT1 (HS00413039_m1)

ZEB2 (Hs00207691_m1)

FAM83H-AS1 (HS01064424_S1)

CDH1 (Hs01023895_m1)

FER1L4 (Hs00957065_g1)

Vimentin (Hs00958111_m1)

UCA1 (Hs01909129_s1)

GAPDH (Hs02786624_g1)

The master mix was vortexed and centrifuged to bring the solution to the bottom
of the tube. 9 μL of each qPCR master mix was loaded into each well of a 96-well
reaction plate, followed by 1 μL cDNA. The plate was sealed, vortexed, and centrifuged
to bring the contents to the bottom of each well and to eliminate air bubbles. The reaction
plate was run on a pre-set thermal cycler program using a Step-One plus qRT-PCR
machine to determine the quantity of each of the lncRNAs in the tested samples.
The -ΔΔCt method was used to determine fold changes.127 The expression of
each examined lncRNA was normalized to GAPDH, using a Ct threshold of 0.1, in order
to calculate ∆Ct values for analysis using the comparative ∆Ct method. Analysis was
completed for expression of each lncRNA for each CRC cell line in comparison to that of
the non-target control lncRNA in the same CRC cell line.

ii. miRNA RT qRT-PCR
After RNA extraction, reverse transcription (RT) was performed in order to
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measure the expression of select miRNAs. The RNA was converted to cDNA using the
TaqMan® miRNA Reverse Transcription Kit, along with specific TaqMan® miRNA
primers (Life Technologies, Carlsbad, CA). The specific miRNA primers consisted of the
following: miR-200b (002251), miR-200c (002300), miR-27a (000408), miR-484
(001821,) and miR-150 (000473). Small nuclear RNA, U6 (001973), was used as a
housekeeper. Once cDNA was created, qRT-PCR was performed, and TaqMan® probes
specific for each miRNA were used in order to measure their expression.
The total reaction volume for each RT reaction was 15μL, and consisted of 7μL
master mix, 3μL TaqMan® miRNA primer, and 5μL RNA at a concentration of 2ng/μL.
The master mix consisted of the following:
Volume per 10 𝝁L reaction (𝝁L)
Component
100mM dNTPs (with dTTP)

0.15

MultiScribe™ Reverse Transcriptase, 50U/μL

1.00

10X Reverse Transcription Buffer

1.50

RNase Inhibitor, 20U/μL

0.19

Nuclease-free water

4.16

TaqMan® miRNA primer (5X)

3.00

Total

10.00

After a master mix was created for each individual miRNA, the contents were
vortexed and centrifuged. The tubes were then placed on ice until further use. RT was
performed using Applied Biosystems® MicroAmp© Optical 96-Well Reaction Plate (Life
Technologies, Carlsbad, CA). 10 μL master mix was pipetted into each well, along with
5μL RNA. The plate was then sealed, vortexed and centrifuged. Once complete, the plate
was then placed into an Eppendorf Mastercyler® nexus (Eppendorf, Hamburg, Germany),
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and run at the following conditions: 16° C for 30 minutes, 42° C for 30 minutes, and 85°
C for 5 minutes. After RT was completed, the cDNA was either stored at -20° C until
further use or immediately used to perform qRT-PCR.
cDNA was quantified using Step-One Plus qRT-PCR machines (Life
Technologies, Carlsbad, CA). Each qRT-PCR reaction was performed in duplicate, with
a final well volume of 10μL. Similar to RT, a master mix was created for each specific
miRNA, and contained the following:

Component

Volume per 10 𝝁L reaction (𝝁L)

TaqMan® MicroRNA Assay (20X)

0.50

TaqMan® Universal Master Mix II, no UNG

5.00

Nuclease-free water

3.17

Product from RT reaction (Minimum 1:15 Dilution)

1.33

Total

10.00

After all the components were added, the master mix was vortexed and
centrifuged. The contents were then added to an Applied Biosystems® MicroAmp© Fast
96-Well Reaction Plate (0.1mL) (Life Technologies, Carlsbad, CA), with each well
receiving 8.67μL master mix followed by 1.33μL cDNA. After loading the plate, it was
sealed, vortexed and centrifuged. The plate was then inserted into a Step-One Plus qRTPCR machine, and run at the following conditions for 40 cycles: 50° C for 2 minutes, 95°
C for 10 minutes, and 60° C for 1 minute.
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The expression of each miRNA was normalized to U6, using a Ct threshold of 1.0
to calculate ΔCt values. Analysis was performed to determine the expression for each
miRNA in all three transfected CRC cell lines, and compared to their expression as seen
in untransfected samples.

i.

Protein Extraction and Quantitation
i. Protein extraction
A solution that consists of 1000 μL of radioimmunoprecipitation assay (RIPA)

buffer (Sigma Aldrich, St. Louis, MO) supplemented with 2 μL protease/phosphatase
inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA) was prepared. The media
from each well in a 6-well plate was removed with a pipette without disturbing the cell
layer. Cells were then lysed and harvested by removing the transfection media and adding
150μL RIPA buffer mix to the six-well plate. A cell scraper was then utilized to collect
the cell lysate. Samples were labeled with the date and experimental conditions. The
samples were frozen and stored at -20°C until processing.
Total protein was processed by sonication with a Sonifier 250 (Branson
Ultrasonics, Danbury, CT). Each sample was sonicated 3 times with 3 pulses per
sonication. The sonicator was cleaned between each sample with a kimwipe and 70%
alcohol. Samples were transferred into 1.5 mL microcentrifuge tubes. The tubes were
then centrifuged at 10,000g for 10 minutes. Pelleted debris was discarded, and the
supernatant extracted and stored at -20°C until quantitated.
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ii. Protein quantitation
Total protein concentrations were quantified in a 96-well plate using a
bicinchoninic acid (BCA) protein quantification assay (Thermo Fisher Scientific,
Waltham, MA). Each sample concentration was measured in duplicate at a 1:20 dilution
with double-distilled water. For each protein sample, 38 μL water was pipetted into a
well and 2 μL protein sample was pipetted into the well. This solution was mixed
thoroughly and 20 μL was pipetted into the well in the row directly adjacent and to the
right (E.g. well a3 -> well a4).
The protein standards were made in the 96-well plate though serial dilution down
the plate (E.g. row A -> H). This serial dilution was performed in duplicate. Forty μL
BCA standard was pipetted into well A1 and A2. Twenty μL of double-distilled water
was pipetted into each well in rows B to row H into both columns 1 and 2. Twenty μL
was sequentially transferred from row A to row G with thorough mixing with each
transfer. Row H contained only 20 μL of distilled water. Equal amounts of Pierce BCA
Protein Assay Reagent A and B (ThermoFisher Scientific, Rockford, IL) were made into
a solution. One hundred sixty μL of this solution was added to each well in the 96-well
plate. The plate was covered and incubated at 37°C for 30 minutes.
BCA assay plates were read on a SPECTRAmax PLUS spectrophotometer
(Molecular Devices, San Jose, CA) at 540 nm. The protein concentrations were then used
to calculate precise amounts of sample and RIPA buffer to be added to protein samples
used for gel electrophoresis.
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j.

Western Blotting
Prior to electrophoresis, protein samples were prepared and denatured with 4X

BoltTM LDS Sample Buffer (Life Technologies) and 2-mercaptoethanol, using a ratio of 1
μL per 100 μL 4X Bolt. Each sample was brought to a total volume of 60 μL with RIPA
buffer. Samples were then heated for 10 minutes at 90 C.
Each denatured protein sample was loaded onto a BoltTM 4-12% Bis-Tris Plus gel
(Invitrogen, Life Technologies, Carlsbad, CA) with BoltTM MES SDS Running Buffer
(Novex, Carlsbad, CA). Each gel was run at 180V for 40 minutes. A dry transfer protocol
on a nitrocellulose membrane was employed using iBlot Gel Transfer Stacks (Invitrogen,
Kiryat Shmona, Israel) with an iBlot transfer system (Invitrogen, Life Technologies,
Carlsbad, CA)
The transfer step was set for 7 or 9 minutes depending on the protein target of
interest. Once completed, cuts were made to the membrane to separate beta actin and
proteins of interest. Membranes were blocked in 5% dry milk in TBST (Tris buffered
saline Tween-20 buffer; Thermo Fisher Scientific) for 1 hour prior to being incubated
with primary antibody for 18 hours at room temperature.
The membranes were incubated with antibodies against E Cadherin 24E10
(1:1000; Cell Signaling, Danvers, MA), Vimentin D21H3 XP (1:1000; Cell signaling,
Danvers, MA), and ZEB1 sc-515797 (1:100; Santa Cruz) in 5% dry bovine serum
albumin in TBST, and Beta actin 8H10D10 (1:5000; Cell Signaling or 1: 50,000; Cell
Signaling) in 5% milk in TBST. Beta actin was used as a cytoplasmic and total protein
internal control.
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The membranes were washed with TBST 3 times following primary antibody
incubation. Secondary HRP-conjugated anti-rabbit antibody 7074S (1:5000; Cell
Signaling) was suspended in 5% milk. Secondary HRP-conjugated anti-mouse antibody
7076 (1:5000; Cell Signaling) was also suspended in 5% milk. For E-cadherin and
Vimentin detection, the anti-rabbit secondary antibody was used. For beta-actin and
ZEB1, the anti-mouse secondary antibody was used. The blot membranes were incubated
in the secondary antibody for 1 hour at room temperature. The membranes were washed
in TBST again prior to imaging. The membrane was incubated in equal proportions of
Enhanced Chemiluminescence (ECL) Reagents A and B (Bio-Rad, Hercules, CA) for 5
minutes to detect target proteins. Immunoblots were developed and imaged using a
ChemiDoc MP imager (Bio-Rad).

k.

Functional Assays
i. Scratch Assay
Cells were plated at 2x106 cells per well in a 6-well plate. This concentration was

selected to allow the cells to grow to confluence in 24 hours. The cells were maintained
in 10% FBS supplemented media. Using a sterile 200μl pipette tip, a single vertical and
horizontal scratch was made. The media was replaced after the scratch was made and at
24-hour time intervals. A representative photo was taken at the time of the initial scratch,
as well as every 24 hours up to 120 hours or until complete scratch closure. Photos were
taken using a Nikon Eclipse TS100 microscope at 4x magnification. The average distance
between the wound edges was calculated for each time point. These average distances
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were used to calculate the percentage closure of the wound compared to the 0-hour time
point. Experiments were completed with at least 3 replicates.

ii. Transwell Migration
After splitting, cells were resuspended in serum-free media (SW480: RPMI-1640
media; HT-29: McCoy’s 5a media; Caco2: EMEM media). The cellular suspension was
pipetted into a polycarbonate membrane insert (COSTAR Transwell Permeable Supports,
8.0μm pore polycarbonate membrane), which was brought up to a final volume of 500 μL
with serum-free media. SW480 cells were seeded at 2 x 105 cells/well, while HT-29 and
Caco2 cells were seeded at 5 x 105 cells/ well. 750 μL complete media (supplemented
with 10% fetal bovine serum) was placed in each well of a 24-well plate to serve as a
chemoattractant. Once the chemoattractant was added, the inserts were placed into their
respective wells. The plate was then incubated at 37°C for 24 hours. After incubation, the
media within the insert was removed. Non -migratory cells were removed with a cotton
swab. Each transwell insert was stained with a Modified Giemsa staining kit (Diff-Quik
staining kit, Electron Microscopy Sciences, Hatfield, PA). The inserts were transferred
through 3 staining solutions, remaining in each solution for 4 minutes. Excess dye in the
upper chamber was removed with a cotton swab. Six pictures were taken of each insert at
10x magnification, and the migratory cells in each of these fields counted and averaged.
Values were reported as medians (with interquartile range). Manual cell counts were
cross-verified with a semi-automatic cell counting software, CELL COUNTER.128
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iii. Proliferation
Cells utilized for proliferation were grown and monitored until the time of use.
Prior to plating, cells were split and their concentration determined. HT-29, SW-480, and
Caco2 cells were each plated at a concentration of 100,000 cells per well in 2% FBS
supplemented media. Cells were plated on a 12-well plate in triplicate. Cells were
counted at the following time points: 24, 48, 72, 96 and 120 hours. At each time point,
media was removed and 250 μL trypsin added to the designated wells at the given time
point. Plates were then incubated for 5 minutes. After incubation, 750 μL media was
added, and the contents of each well were thoroughly mixed. Two 10 μL samples from
each well were then pipetted into a dual chamber cell slide (Bio-Rad Laboratories,
Hercules, CA) and inserted into an automatic cell counter (TC20TM Bio-Rad
Laboratories, Hercules, CA) to obtain daily cell counts. Cell counts from each replicate
for the given time points were averaged. The average cell counts from the non-target cells
were then compared to those of the siRNA-transfected cells.
Twenty μL samples from each well were pipetted into a microtube, and 20 μL of Trypan
blue was added. This solution was mixed thoroughly with a pipette. Ten μL of the mixed
solution was added to each of the chambers of the dual chamber cell slide (Bio-Rad
Laboratories, Hercules, CA) and inserted into an automatic cell counter (TC20TM BioRad Laboratories, Hercules, CA) to obtain the percentage of viable cells.

l.

Statistical Analysis:
All statistical analysis was performed using SPSS v25.0 (IBM Corp, Armonk

NY). Continuous data is reported as the median value with the inter-quartile range.
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Categorical data is reported as the frequency and percentage. For comparisons between,
continuous data, the independent samples t-test or Mann-Whitney U test were used,
where appropriate. For comparisons between categorical data, the Chi-squared test, or
the Fischer’s exact test was used, where appropriate. All statistical tests were two-tailed
and a statistical test was considered significant with a p-value of <0.05.

81

CHAPTER VII

VALIDATION OF lncRNA EXPRESSION IN HUMAN SAMPLES AND IN
COLON ADENOCARCINOMA CELL LINES

a)

Introduction

As described in the previous chapters, seven lncRNAs were identified to be
significantly increased in colon adenocarcinoma samples compared to adjacent normal
tissue and were selected for further study. There are, however, some issues with using
data from The Cancer Genome Atlas. The tissue that is used for RNA-seq is from a
macro-dissected tumor sample. Therefore it includes not only cancer cells, but also the
stroma, with its content representing the tumor microenvironment.113 Previous studies
have shown that the tumor microenvironment can skew data analysis by “contaminating”
the actual tumor expression of target molecules such a miRNA.34 In addition, cells from
within the tumor microenvironment may express or secrete lncRNAs in order to induce
an effect on cancer cells.94 In this case, whole tissue dissection may lead to the false
conclusion that the lncRNA is expressed from the cancer cells instead of from cells
within the tumor microenvironment.
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There is therefore a need to verify tissue expression in both clinical samples and in
cell lines for in vitro mechanistic and functional analysis. We hypothesized that the
selected lncRNAs would have an increased expression in colon adenocarcinoma
compared to normal colon epithelium. In addition, we aimed to characterize each of the
lncRNA, which were found to be significantly increased in the clinical samples, in terms
of their cellular location in our colon cancer cell lines, as this may help to delineate their
mechanism of action. For lncRNAs that are principally located in the cytoplasm, this may
suggest that the lncRNA has its effect through a competitive endogenous RNA
mechanism.

b)

Results

1.

Expression of the seven identified lncRNAs in human samples

Patient details from the University of Louisville biorepository are shown in table 5.
Using laser capture Microdissection (LCM), cells were obtained from colon
adenocarcinoma samples along with paired normal colon epithelium from the same
patient. We then determined the difference in expression of the 7 selected lncRNA’s
between the two tissues. All normal colon epithelium samples were taken 10cm from the
colon carcinoma.
Three of the seven lncRNAs, PVT1, GAS5, and ZFAS1 were significantly
upregulated in colon adenocarcinoma samples compared to the paired normal colon
epithelium (Fold regulation= 2.75, p=0.003, Fold regulation= 1.70, p=0.021, and Fold
regulation=3.06, p<0.001) (Figure 17 and 18). In contrast, FAM83H-AS1 and UCA1
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Table 5. Clinical details of patients from the University of Louisville Biorepository

N=23
N(%)

Variable
Age at diagnosis(years) (median, Interquartile Range)
Gender
Male
Female
Race
Caucasian
African-American
AJCC Tumor Stage
Stage I
Stage II
Stage III
Stage IV
AJCC- American Joint Committee on Cancer
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70 (61-77)
16 (70)
7 (30)
17(74)
6(26)
7(30)
6(26)
5(22)
5(22)

Figure 17. Differential expression of the 7 identified lncRNAs between colon
adenocarcinoma compared to paired normal colon epithelium in laser capture
microdissection samples.

PVT1, GAS5, and ZFAS1 (green) were significantly increased in colon
adenocarcinoma compared to normal colon epithelium. FAM83H-AS1 and UCA1 (red)
were significantly decreased in colon adenocarcinoma compared to normal colon
epithelium.
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Figure 18. Individual differences in lncRNA expression between normal colon
epithelium and colon adenocarcinoma for each of the samples that underwent laser
capture microdissection.; a) FAM83H-AS1, b) PVT1, c) UCA1, d) H19, e) FER1L4, f)
GAS5, g) ZFAS1.

There was significantly decreased expression of FAM83H-AS1 in colon
adenocarcinoma cells compared to that of normal colon epithelium.
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There was significantly increased expression of PVT1 in colon adenocarcinoma
cells compared to that of normal colon epithelium.
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There was significantly decreased expression of UCA1 in colon adenocarcinoma
cells compared to that of normal colon epithelium.
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There was no difference in the expression of H19 in colon adenocarcinoma cells
compared to that of normal colon epithelium.
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There was no difference in the expression of FER1L4 in colon adenocarcinoma
cells compared to that of normal colon epithelium.
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There was significantly increased expression of GAS5 in colon adenocarcinoma
cells compared to that of normal colon epithelium.

91

There was significantly increased expression of ZFAS1 in colon adenocarcinoma
cells compared to that of normal colon epithelium.
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were significantly downregulated in the colon adenocarcinoma samples compared to
normal colon epithelium (Fold regulation= -3.68, p<0.001 and fold regulation= -4.85,
p<0.001).

2.

Verification of cell line lncRNA expression and baseline lncRNA

expression in 3 colon adenocarcinoma cell lines
The Cancer Cell Line Encyclopedia is a public bioinformatics repository from the
Broad Institute that has RNA-sequencing data on cancer cell lines.118 We employed this
database to examine for expression of the selected lncRNAs in each of the three cell lines
(Table 6). This database was also used to verify the given cell lines as an appropriate
model for studying the in vitro function of the specific lncRNAs. The three cell lines used
were: HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown). Both GAS5 and
ZFAS1 had considerable expression in all 3 of the cell lines, as compared to the other
lncRNAs.
By utilizing the RNA-sequencing data from The Cancer Genome Atlas, we sought
to examine the expression of lncRNAs which were confirmed to be significantly
increased in colon cancer compared to normal colon epithelium, and that were
significantly represented in our cell line models. We therefore proceeded with the
examination of PVT1, GAS5, and ZFAS1 in all three cell lines.
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3.

Cellular localization of lncRNAs in the 3 colon adenocarcinoma cell lines

To further characterize the 3 selected lncRNAs, we examined their subcellular
location in each of the cell lines. The Protein And RNA Isolation System (PARIS) kit
was used for this purpose. This kit facilitates the separation of the nuclear compartment
from the cytoplasmic compartment, which allows for the examination of RNA and/or
expression in each respective compartment.
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Table 6. RNA-seq expression of the 7 lncRNA in each of the three cell lines.
FAM83H-AS1

PVT1

UCA1

H19

FER1L4

GAS5

ZFAS1

Log2(FPKM)

Log2(FPKM)

Log2(FPKM)

Log2(FPKM)

Log2(FPKM)

Log2(FPKM)

Log2(FPKM)

- 0.08953

2.686195

1.35313

- 1.81046

- 3.55516

6.962189

8.12454

4.119231

3.494942

1.50359

- 0.7996

4.946835

6.707078

6.850634

3.426141

0.871515

5.606888

2.45024

- 1.78887

6.341947

8.056874

Cell line

HT29
Stage III
SW480
Stage II
Caco2
Stage
Unknown
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ZFAS1 was significantly increased in the cytoplasmic fraction compared to the
nuclear fraction of all 3 cell lines (HT29: 76% vs. 24%, p=0.02, SW480: 84% vs. 16%,
p=0.03, Caco2 77% vs. 23%, p=0.005) (Figure 19). Similarly, GAS5 was also
significantly increased in the cytoplasmic fraction compared to the nuclear fraction in all
3 cell lines (HT29: 79% vs. 21%, p=0.02, SW480: 84% vs. 16%, p=0.003, Caco2 77%
vs. 23%, p=0.008) (Figure 20). In contrast, PVT1 was more expressed in the nuclear
fraction compared to the cytoplasmic fraction (HT29: 87% vs. 13%, p=0.005, SW480:
80% vs. 20%, p=0.1, Caco2 64% vs. 36%, p=0.004) (Figure 21).

4.

Efficiency and fold regulation of lncRNA knockdown in 3 colon
adenocarcinoma cell lines

The expression of the three lncRNAs was examined in each of the 3 cell lines
following transfection with either ZFAS1 siRNA, PVT1 siRNA, GAS5 siRNA, or with
non-targeting siRNA. In the HT29 cell line, there was efficient knockdown of both
ZFAS1 and GAS5, but not PVT1 compared to cells transfected with non-target siRNA
(Figure 22a-c). Accordingly, there was a significant decrease in expression of ZFAS1 and
GAS5 compared to non-target siRNA (Fold regulation= -2.95, p<0.001, Fold regulation=
-4.75, p=0.002 respectively.) (Figure 22d)
Similarly, in the SW480 cell line there was efficient knockdown of both ZFAS1
and GAS5, but not PVT1 compared to cells transfected with non-target siRNA (Figure
23a-c). As expected, there was a significant decrease in expression of ZFAS1 and GAS5
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Figure 19. Subcellular distribution of ZFAS1 in each of the three colon adenocarcinoma
cell lines. In each of the three cell lines, ZFAS1 was significantly increased in the
cytoplasm (highlighted in blue) compared to that of the nucleus (highlighted in orange)
(HT29: p=0.02, SW480, p=0.03, Caco2, p=0.005).
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Figure 20. Subcellular distribution of GAS5 in each of the three colon adenocarcinoma
cell lines. In each of the three cell lines, GAS5 was significantly increased in the nucleus
(highlighted in orange) compared to that of the cytoplasm (highlighted in blue) (HT29:
p=0.005, SW480, p=0.1, Caco2, p=0.004).
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Figure 21. Subcellular distribution of PVT1 in each of the three colon adenocarcinoma
cell lines. In each of the three cell lines, PVT1 was significantly increased in the
cytoplasm (highlighted in blue) compared to that of the nucleus (highlighted in orange)
(HT29: p=0.02, SW480, p=0.003, Caco2, p=0.008).

99

Figure 22. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to
non-targeting siRNA in the HT29 cell line. There is significant knockdown of ZFAS1 (a)
and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of
ZFAS1 and GAS5 compared to non-target siRNA (d)
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compared to non-target siRNA (Fold regulation= -9.96, p<0.001, Fold regulation= -9.79,
p<0.001 respectively.) (Figure 23d).
Finally, in the Caco2 cell line there was efficient knockdown of both ZFAS1 and
GAS5, but not PVT1 compared to cells transfected with non-target siRNA (Figure 24ac). There was a significant decrease in expression of ZFAS1 and GAS5 compared to
non-target siRNA (Fold regulation= -5.28, p<0.001, Fold regulation= -7.18, p=0.01
respectively) (Figure 24d).

101

Figure 23. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to
non-targeting siRNA in the SW480 cell line. There is significant knockdown of ZFAS1
(a) and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of
ZFAS1 and GAS5 compared to non-target siRNA (d)
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Figure 24. Efficiency of knockdown of ZFAS1, PVT1, and GAS5 compared to
non-targeting siRNA in the CACO2 cell line. There is significant knockdown of ZFAS1
(a) and GAS5 (c) but not PVT1 (b). There is significant decreased in fold regulation of
ZFAS1 and GAS5 compared to non-target siRNA (d)
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C)

Discussion
Utilizing the TCGA database, we have identified that 7 lncRNAs showed

increased expression in colon adenocarcinoma compared to normal colon epithelium. We
aimed to verify the expression of each of the selected lncRNAs in clinical samples that
underwent laser capture microdissection. Three of the lncRNAs were increased in
expression compared to the paired normal colon epithelium sample, which importantly
matched the direction of expression identified from The Cancer Genome Atlas. In
contrast, two of the lncRNAs were significantly decreased in the colon adenocarcinoma
sample compared to that of the paired normal colon epithelium. Furthermore, all 3 cell
lines had robust expression of ZFAS1, GAS5, and PVT1, which were chosen for further
investigation. Upon examining the subcellular location of each of these 3 lncRNAs,
ZFAS1 and GAS5 were located mainly in the cytoplasm compared to PVT1, which was
located mainly in the nucleus. When the efficiency of knockdown with a siRNA against
each of the three lncRNAs was examined, robust knockdown was only observed with
ZFAS1 and GAS5.
It is important to characterize and validate the expression of molecules from highthroughput sequencing databases with institutional clinical samples. As previously
mentioned, molecules can have differential expression depending on the intra-tumoral
location (e.g. surface of the colon vs. the invasive border of the tumor), or the cell from
which the RNA is expressed (e.g. immune cell in the microenvironment vs. colon
adenocarcinoma cell). Interestingly, UCA1 was significantly decreased in our
institutional samples which support Jahaingiri et al. who hypothesize that UCA1 is
expressed by cancer associated fibroblasts as opposed to colon adenocarcinoma cells.94
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In addition, the cellular localization of lncRNAs helps to define their function.
RNA interference typically occurs in the cytoplasm of a cell, as the RISC complex and
the other machinery for this function occurs in the cytoplasm. microRNAs and small
interfering RNAs both mediate their function in an RNA interference-based mechanism,
to either repress the translation of a mRNA or to degrade the transcript in the cytoplasm.
Therefore, one would suspect that a lncRNA located in the cytoplasm would be more
likely to perform its principal function in the cytoplasm, such as that of a competitive
endogenous RNA function. This hypothesis is supported by the results of the knockdown
experiments, as PVT1, which is a nuclear located lncRNA does not have significant
knockdown with transfection of siRNA. This is in contrast to that of both ZFAS1 and
GAS5, which are located in the cytoplasm and have robust knockdown with siRNA. The
further examination of PVT1 would require an alternative method to investigate its
function in vitro, such as the use of CRISPR-based technology.
As both GAS5 and ZFAS1 were significantly increased in expression in colon
adenocarcinoma, compared to normal colon epithelium, and there was reproducible
knockdown of both GAS5 and ZFAS1 with siRNA transfection, we selected ZFAS1 and
GAS5 for further investigation in an in vitro cell line model.
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CHAPTER VIII

EFFECT OF lncRNA ZFAS1 AND GAS5 KNOCKDOWN ON COLON CANCER CELL LINE
PHENOTYPE

a) Introduction

The lncRNAs from previous chapters selected for further in vitro investigation were
GAS5 and ZFAS1. Both lncRNAs were increased in colon cancer compared to normal colon
epithelium and were located in the cytoplasmic cellular compartment. This suggested that both
lncRNAs had a competitive endogenous RNA mechanism. Therefore, as a means of delineating a
preferred candidate, we aimed to characterize the function of these lncRNAs in terms of their
effect on colon cancer phenotype.
As previously mentioned, both lncRNAs were predicted to mediate an effect on cellular
proliferation and migration. We hypothesized that at least one of these lncRNAs would mediate a
larger effect on cellular proliferation, and that from these data, a single candidate lncRNA could
be identified to investigate cellular migration. Although lncRNAs may be predicted to have an
effect on cellular function, a large number of these molecules do not mediate an effect on cellular
function. Therefore, the purpose of these experiments was to verify and validate the effect of
lncRNA knockdown on cellular function, with lncRNAs that were identified to be increased in
expression in colon adenocarcinoma compared to normal colon epithelium.
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b) Results
1) Knockdown of ZFAS1, but not GAS5, leads to reduced cell proliferation in colon cancer cell
lines
Colon cancer cell lines, HT29 (Stage III) SW480 (Stage II), and Caco2 (Stage Unknown), were
transfected with ZFAS1 siRNA, GAS5 siRNA, or non-targeting siRNA to examine for
differences in cellular proliferation. The cell viability of each transfected well was checked for
cell viability and were >90-95% for all transfections. Cell viability demonstrated that all cells had
Cells were transfected for 48 hours in 6-well plates, and then plated in 12-well plates to examine
cellular proliferation. Cells counts were examined every 24 hours for five consecutive days.
In both the HT-29 and the SW-480 cell lines, ZFAS1 knockdown led to reduced cellular
proliferation compared to cells transfected with non-target siRNA (Figure 25a, 26a). In contrast,
there was no difference in the cellular proliferation of the Caco2 cell line between cells
transfected with ZFAS1 siRNA compared to non- target siRNA (Figure 27a).
In all three cell lines, there was no difference in cellular proliferation of cells transfect with GAS5
siRNA compared to non-target siRNA (Figure 25b, 26b, 27b).
Therefore, we chose to focus the remainder of the in vitro experiments on the effect of ZFAS1 on
cellular phenotype.

2) Knockdown of ZFAS1 leads to reduced migration of colon cancer cells
All 3 colon cancer cell lines, HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown),
were transfected with either ZFAS1 siRNA or non-target siRNA. Following transfection and
plating for scratch analysis, photographs of the scratch were taken every 24 hours up to scratch
closure or to 120 hours after the scratch was made.
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Figure 25. Proliferation of the HT-29 cell line following transfection with a) ZFAS1 siRNA and
b) GAS5 siRNA, compared to transfection with non-target siRNA.

*
*

*P=0.02

There is decreased proliferation of the SW-480 cell line with transfection of ZFAS1 siRNA
compared to non-target siRNA at 96 hours (*P=0.02) and 120 hours (*P=0.02). There is also a
significant decrease in the doubling time of the cells transfected with ZFAS1 siRNA compared to
non-target siRNA (P=0.04). There was no difference in the proliferation of cells transfected with
GAS5 siRNA compared to non-target siRNA
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Figure 26. Proliferation of the SW-480 cell line following transfection with a) ZFAS1 siRNA and
b) GAS5 siRNA, compared to transfection with non-target siRNA.

**
*

* P=0.03
**P=0.02

*

There is decreased proliferation of the SW-480 cell line with transfection of ZFAS1 siRNA
compared to non-target siRNA at 72 hours (*P=0.03), 96 hours (*P=0.03), and 120 hours
(**P=0.02). There is also a significant decrease in the doubling time of the cells transfected with
ZFAS1 siRNA compared to non-target siRNA (P=0.01). There was no difference in the
proliferation of cells transfected with GAS5 siRNA compared to non-target siRNA (All P>0.05)
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Figure 27. Proliferation of the Caco2 cell line following transfection with a) ZFAS1 siRNA and
b) GAS5 siRNA, compared to transfection with non-target siRNA.

There was no difference in the proliferation of Caco2 cells transfected with ZFAS1 siRNA or
GAS5 siRNA compared to non-target siRNA (all P>0.05)
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As expected, ZFAS1 knockdown lead to decreased scratch closure in the HT29 cell line at 120
hours (Figure 25a). In addition, ZFAS1 knockdown lead to decreased scratch closure in the
SW480 and Caco2 cell line at 48 hours (Figure 25b, c).

3) Knockdown of ZFAS1 leads to decreased transwell migration of colon cancer cells.
The 3 colon cancer cell lines, HT29 (Stage III), SW480 (Stage II), and Caco2 (Stage Unknown),
were transfected with either ZFAS1 siRNA or non-target siRNA. After 24 hours’ incubation in a
transwell insert, each insert was examined for migrated cells. There was decreased migration of
each of the cell lines transfected with ZFAS1 siRNA compared to non-target siRNA (Figure 26).
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Figure 28. Functional cell migration as measured by the scratch assay of the a) HT-29 cell line, b)
SW480 cell line, and the c) Caco2 cell line with transfection of ZFAS1 siRNA compared to
transfection with non-target siRNA. In all 3 cell lines there was slower scratch closure of cells
transfected with ZFAS1 siRNA compared to non-target siRNA.
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Figure 29. Transwell migration of the a) HT-29 cell line, b) SW480 cell line, and the c) Caco2
cell line with transfection of ZFAS1 siRNA compared to transfection with non-target siRNA. In
all 3 cell lines there was decreased migration of cells transfected with ZFAS1 siRNA compared to
non-target siRNA.
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c) Discussion
These data demonstrate that ZFAS1 knockdown in colon cancer cell lines leads to a less
aggressive phenotype than that of cells transfected with non-target siRNA. In two different
functional experiments, ZFAS1 knockdown led to decreased cells growth and reduced cell
migration. These results indicate that ZFAS1 may have a role as a mediator of cellular function in
vitro.
Interestingly, there was no difference in Caco-2 cell line proliferation. This is likely due
to the fact that the doubling time of the Caco-2 cell line is quite slow at 62 hours. We were
therefore unable to detect a difference in these slow growing cells over the time course of the
experiment.126 In contrast, knockdown of ZFAS1 in the other two cell lines, HT-29 and SW-480,
led to reduced cellular proliferation.
There was more marked transwell migration of the SW480 cell line compared to the
Caco-2 and HT-29 cell lines. This is an expected observation, as the SW480 cell line has a
mesenchymal phenotype and has a Consensus Molecular Subytpe 4 classification.126 In contrast,
the HT29 cell line is characterized by a more rapid proliferation than the SW-480 cell line. This
too is an expected result, as the HT-29 cell line has an epithelial phenotype and has a Consensus
Molecular Subtype 3 classification.
Knockdown of GAS5 did not lead to a change in proliferation compared to non-target
siRNA. GAS5 is typically described to have a tumor suppressor function. This may in part
explain why knockdown did not lead to increased cell growth.129 Although GAS5 expression is
significantly increased in colon cancer in The Cancer Genome Atlas database and this was
validated in our institutional samples, another study on colorectal cancer found GAS5 to be
reduced in expression compared to normal tissue.130
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The results of these experiments indicate that ZFAS1 is a good target for further
mechanistic studies to delineate how it mediates its effect on tumor progression.
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CHAPTER IX

ZFAS1 HAS A RECIPROCAL RELATIONSHIP WITH MIR-200B AND MIR-200C

a)

Introduction

In our previous experiments, we demonstrated that knockdown of ZFAS1 leads to
a decrease in cell proliferation and cell migration as measured by the proliferation assay
and transwell migration and scratch assays respectively. Furthermore, we demonstrated
that ZFAS1 is predominantly located in the cytoplasm, which suggests that it carries out
its principal mechanism there. These data suggest that ZFAS1 plays a role in the
epithelial-mesenchymal transition of cancer cells. Additionally, ZFAS1 has recently been
identified to have a complex role in tumor signaling in different cancers.111
We propose that by manipulating ZFAS1 expression in our three colon cancer cell
lines, that we will affect the expression of target miRNAs. These target miRNAs have
been identified by using a bioinformatics predication tool, and have also been
experimentally verified in the literature through positive luciferase reporter assays or
RNA pulldown assays. Utilizing siRNA that target against ZFAS1, we hypothesize that
we will see a reciprocal increase in expression of the target miRNAs. As further evidence
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to support this, we hypothesize that use of identified miRNA mimics will lead to a
reciprocal decrease in ZFAS1 expression. The rationale for these experiments is to verify
the interaction between ZFAS1 and the experimentally verified miRNA targets to help
describe the signaling pathway with which ZFAS1 is associated.

b)

Results
lncRNA: miRNA Bioinformatics Prediction
LncBase (http://carolina.imis.athena-

innovation.gr/diana_tools/web/index.php?r=lncbasev2%2Findex-experimental) is a
bioinformatics tool containing algorithmically predicted and experimentally verified
miRNA targets for lncRNAs.131 This program functions by entering ENSEMBL ID codes
for a given lncRNA or entering the miRBase ID code for a miRNA. This experimentally
verified tool was employed to identify targets for ZFAS1. The original citing literature
was identified. Five miRNA targets were identified from the LncBase program (Figure
27) that have an experimentally confirmed direct binding to ZFAS1. (Table 7)
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Figure 30. Binding sites of ZFAS1 and selected miRNA from the LncBase server.

ZFAS1 binds to each of the miRNA at different sites along the transcript length.
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Table 7- Literature reported microRNA interactions for the lncRNA ZFAS1
Method of experimental
lncRNA

miRNA

Literature citation
verification
Liu G. et al132

RNA immunoprecipitation

Zhang F et al133

RNA pulldown assay

miR-200c

Liu G. et al132

RNA immunoprecipitation

miR-150

Xia B. et al134

Luciferase reporter assay

Li T. et al135

RNA pulldown assay

Wu T. et al136

RNA pulldown assay

Chen X et al.137

RNA pulldown assay

miR-484

Xie S et al.138

RNA immunoprecipitation

miR-27a

Ye Y et al.139

RNA pulldown assay,

miR-200b

ZFAS1

Luciferase reporter assay
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miRNA expression following ZFAS1 siRNA transfection
miRNA expression was analyzed over three time points; 24, 48, and 72 hours. ZFAS1
knockdown was verified using qRT-PCR. In the HT29 cell line, miR-200b was
significantly increased at 24 (Fold change= 3.34, p=0.011) and 48 hours (Fold
change=2.28, p=0.012) after transfection with ZFAS1 siRNA. miR-200c was also
significantly increased in expression at 24 hours (Fold change= 2.19, p=0.038) after
transfection with ZFAS1 siRNA. miR-27a was significantly increased in expression after
48 hours (Fold change =6.70, p=0.020). There was no difference in the other miRNA at
the time points examined (Figure 28). In the SW480 cell line, miR-200b was increased at
24 hours (Fold change=6.69, p=0.005) and at 48 hours (Fold change= 1.88, p=0.022)
after transfection with ZFAS1 siRNA. In addition, miR-200c was increased at 24 hours
(Fold change= 6.53, p=0.010) and 48 hours (Fold change=1.80, p=0.025) after
transfection. Similar to the HT29 cell line, there was no difference in the other miRNA
examined at the time points. (Figure 29)
ZFAS1 expression following miR-200b and miR-200c mimic transfection
ZFAS1 expression was measured over the same three time points; 24, 48, and 72 hours
after transfection of miR-200b and miR-200c mimics. In the HT29 cell line, transfection
with miR-200b mimics and miR-200c mimics resulted in decreased ZFAS1 expression at
48 hours after transfection (Fold change= -2.49, p=0.005 and Fold change= -3.60,
p=0.002 respectively) (Figure 30). Similarly, transfection with miR-200b mimics and
miR-200c mimics in the SW480 cell line resulted in decreased ZFAS1 expression at 48
hours after transfection (Fold change= -2.24, p=0.03 and fold change= -2.21, p=0.007
respectively) (Figure 31).
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Figure 31. Expression of selected miRNA in the HT29 cell line following ZFAS1 siRNA
transfection at; a) 24 hours after transfection and b) 48 hours after transfection.
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Figure 32. Expression of selected miRNA in the SW480 cell line following ZFAS1
siRNA transfection at a) 24 hours after transfection and b) 48 hours after transfection.
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Figure 33. Expression of ZFAS1 in the HT29 cell line following; a) miR-200b mimic
transfection, and b) miR-200c mimic transfection.
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Figure 34. Expression of ZFAS1 in the SW480 cell line following; a) miR-200b mimic
transfection, and b) miR-200c mimic transfection.
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Transfection with miR-200b and miR-200c mimics produces the same phenotype as cells
transfected with ZFAS1 siRNA
As a proof of concept to demonstrate the relationship between miR-200b, miR200c, and ZFAS1, we performed a scratch assay and transwell migration assay
comparing cells transfected with miR-200b and miR-200c mimics compared to negative
control.
As expected, cells transfected with both miR-200b and miR-200c mimics had
slower scratch closure compared to non-target siRNA, in the HT29 cell line (p<0.001,
and p=0.004 respectively) (Figure 32). There was also decreased transwell migration of
cells transfected with miR-200b and miR-200c mimics compared to non-target siRNA
(both p=0.031) (Figure 33).
In the SW480 cell line, there was also a slower scratch closure in cells transfected
with mi-200b and miR-200c mimics compared to negative control (p=0.002 and p<0.001
respectively) (Figure 34). Similarly, there was decreased transwell migration of cells
transfected with miR-200b and miR-200c mimics compared to negative control (p=0.009
and p=0.004 respectively) (Figure 35)
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Figure 35. There was decreased scratch closure of HT29 cells transfected with miR-200b
and miR-200c mimics compared to negative control.
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Figure 36. There was decreased transwell migration of HT29 cells transfected with miR200b and miR-200c mimics compared to negative control.
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Figure 37. There was decreased scratch closure of SW480 cells transfected with miR200b and miR-200c mimics compared to negative control.
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Figure 38. There was decreased migration of SW480 cells transfected with miR-200b and
miR-200c mimics compared to negative control
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c)

Discussion

The results of these experiments support the hypothesis that ZFAS1 directly binds to
miR-200b and to miR-200c. ZFAS1 knockdown with siRNA leads to increased
expression of the two miR-200 family members at two time points, and transfection with
miR-200b and miR-200c mimics leads to decreased ZFAS1 expression. Interestingly,
changes in the other miRNA targets were not consistently observed following ZFAS1
knockdown.
The changes in RNA expression occur at 24-48 hours after transfection when using
siRNA and miRNA mimics to regulate gene expression. This is the timeframe in which
changes of RNA expression are expected to occur when transfecting with these
molecules.
The miR-200 family is a well-described mediator of EMT and as a proof of concept, the
functional experiments for migration demonstrated that miR-200b and miR-200c both
lead to decreased migration. As previously mentioned, ZFAS1 knockdown also leads to
decreased cell migration, and when considering that ZFAS1 has a reciprocal relationship
with miR-200b and miR-200c, this suggests that they may share a common signaling
pathway through which this effect is mediated.
Consequently, this relationship was chosen for further study. These results support the
competitive endogenous RNA hypothesis, in that ZFAS1 can act as a “molecular sponge”
for target miRNA, and that ZFAS1 could be a target for regulating cell function.
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CHAPTER X

EFFECT OF ZFAS1 EXPRESSION ON THE ZEB1/E-CADHERIN, VIMENTIN TARGET
SIGNALING PATHWAY

a)

Introduction

In the previous chapter, we demonstrated that ZFAS1 has a reciprocal relationship both
miR-200b and miR-200c. When these results are considered in relation to the phenotypic results
of decreased migration with ZFAS1 knockdown, these effects may be regulated through miR200/ZEB1/E-Cadherin, vimentin signaling.
The miR-200 family is a well described major regulator of epithelial-mesenchymal
transition (EMT).40 This is a critical factor involved in cancer metastasis. Loss of miR-200 family
expression is observed at the invasive borders of colorectal cancer pathology specimens34 and is
associated with adverse clinical outcomes.40 The miR-200 family does have a dichotomous role
of also increasing cancer proliferation through different signaling pathways.53,140
The signaling pathway through which ZFAS1 is associated with the miR-200 family has
not, however, been completely defined. We hypothesized that ZFAS1 knockdown would lead to
decreased expression of ZEB1. Furthermore, to validate the phenotypic results observed, we
hypothesized that ZFAS1 knockdown would lead to an increase in an epithelial marker, E-
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Cadherin, and a decrease in a mesenchymal marker, Vimentin. The rationale for these
experiments is to validate an associated signaling pathway through which ZFAS1 and miR-200b
and miR-200c have an effect.

b)

Results

ZFAS1 knockdown leads to decreased ZEB1 RNA and protein expression
After successful transfection of the HT-29 cell line with ZFAS1 siRNA and non-target
siRNA there was significant decrease in ZEB1 mRNA expression compared to non-target siRNA
(Fold regulation= -2.68, p=0.031) (Figure 39). As also expected, transfection with miR-200b and
miR-200c mimics leads to decreased ZEB1 mRNA compared to non-target siRNA (Fold
regulation= -3.19, p=0.03, and fold regulation= -1.82 p=0.04). (Figure 39)
As a further proof of concept, there was a significant decrease in ZEB1 protein
expression as examined by western blots in cells transfected with ZFAS1 siRNA compared to
non-target siRNA (Figure 40).
Similarly, in the SW-480 cell line, there was a significant decrease in ZEB1 mRNA
expression after transfection with ZFAS1 siRNA compared to cells transfected with non-target
siRNA (Figure 3). Transfection with miR-200b and miR-200c mimics also lead to decreased
ZEB1 gene expression compared to non-target siRNA (Figure 41).
When ZEB1 protein expression was examined with western blotting there was a
significant decrease in expression in cells transfect with ZFAS1 siRNA compared to non-target
siRNA (Figure 42).
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ZFAS1 knockdown leads to decreased Vimentin protein expression
To further support the functional data described in an earlier chapter, indicating that
ZFAS1 is associated with EMT, we examined for differences between cells transfected with
ZFAS1 siRNA compared to non-target siRNA. In the HT-29 cell line there was a significant
decrease in vimentin with ZFAS1 knockdown compared to non-target siRNA. (Figure 43a)
Similarly, in the SW480 cell line, there was a significant decrease in vimentin with ZFAS1
knockdown compared to non-target siRNA (Figure 43b).
ZFAS1 knockdown leads to increased E-Cadherin expression
As expected, HT29 cells transfected with ZFAS1 siRNA had significantly increased Ecadherin expression compared to cells transfected with non-target siRNA. (Figure 44a) There was
a significant increase in E-cadherin expression in the SW480 cells transfected with ZFAS1
siRNA compared to non-target siRNA (Figure 44b).
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Figure 39. ZEB1 gene expression in the HT-29 cell line following transfection with ZFAS1
siRNA, miR-200b mimics, and miR-200c mimics compared to non-target siRNA. There is
significant decrease in ZEB1 expression in all 3 conditions compared to non-target siRNA.
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Figure 40. ZEB1 protein expression in the HT29 cell line in cells transfected with ZFAS1 siRNA
or non-target siRNA. There is significantly decreased ZEB1 expression following transfection
with ZFAS1 siRNA compared to non-target siRNA.
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Figure 41. ZEB1 gene expression in the SW480 cell line following transfection with ZFAS1
siRNA, miR-200b mimics, and miR-200c mimics compared to cells transfected with non-target
siRNA. There is significant decrease in ZEB1 expression in all 3 conditions compared to nontarget siRNA.
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Figure 42. ZEB1 protein expression in the HT29 cell line in cells transfected with ZFAS1 siRNA
or non-target siRNA. There is significantly decreased ZEB1 expression following transfection
with ZFAS1 siRNA compared to non-target siRNA.
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Figure 43. Vimentin expression in the HT29 and SW480 cell lines transfected with ZFAS1
siRNA or with non-target siRNA. There is decreased vimentin expression in both cell lines
transfected with ZFAS1 siRNA compared to non-target siRNA.
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Figure 44. E-Cadherin expression in the HT29 and SW480 cell lines transfected with ZFAS1
siRNA or with non-target siRNA. There is increased E-cadherin expression in both cell lines
transfected with ZFAS1 siRNA compared to non-target siRNA.
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c)

Discussion

The results of these experiments indicate that ZFAS1 is associated with an effect on
ZEB1 RNA and protein expression, which is a direct target of miR-200b and miR-200c.
Furthermore, ZFAS1 regulates E-Cadherin and vimentin expression, which are both important
proteins in EMT. When these results are considered in the context of the previous experiments
indicating that ZFAS1 has a direct interaction with the miR-200 family, and that ZFAS1
knockdown leads to decreased migration, we concluded that ZFAS1 knockdown was associated
with EMT through the ZEB1/E-Cadherin, Vimentin signaling cascade.
From RNA-sequencing data in the Cancer Cell Line Encyclopedia, there is relatively low
expression of ZEB1 in both the HT29 and SW480 cell line, which is reflected in the western blot
data shown in this chapter. For ZEB1 expression, a larger protein load (100ng) was used to
facilitate band detection in both cell lines.
There is robust E-Cadherin expression and relatively lower vimentin in the HT29 cell line
when examining the western blotting data. The HT29 cell line is an epithelial-like cell line126,
which is reflected in its Consensus molecular subtype 3 classification, and in its RNA-sequencing
profile as assessed by the Cancer Cell Line Encyclopedia.118 In contrast, there is more robust
vimentin expression and relatively lower E-Cadherin expression in the SW480 cell line when
examining the western blotting data. This, again, is reflected in its mesenchymal Consensus
Molecular Subtype 4 classification126, and its RNA-sequencing profile as assessed by the Cancer
Cell Line Encyclopedia.118
Typically, EMT is associated with decreased migration and increased proliferation, and
many of the studies that investigate the miR-200 family as a regulator of EMT recapitulate these
results.40 However, as previously mentioned, some studies have indicated that it may also lead to
increased proliferation through alternative signaling pathways.52,53 The presented data suggest
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that ZFAS1 knockdown was associated with a signaling pattern consistent with EMT in that there
is changes in ZEB1, E-Cadherin, and Vimentin expression. A recent study investigating ZFAS1
also demonstrated that it regulated migration and proliferation through another signaling cascade,
miR-150-5p/VEGFA.137
In the context of the previous chapters, ZFAS1 knockdown is consistent with both the
functional effects of EMT signaling and with the major EMT signaling cascade miR200/ZEB1/E-cadherin, Vimentin.

143

CHAPTER XI

DISCUSSION AND CONCLUDING REMARKS

We hypothesized that the use of an RNA-sequencing data set to compare the entire
transcriptome of colon adenocarcinoma tissue to paired normal colon epithelium tissue would
allow us to investigate specifically differentially expressed lncRNAs. As a number of studies
have shown that lncRNAs can have different roles in different cancers, it is important to
investigate their specific role in colon adenocarcinoma. This improves the understanding of
cellular signaling, and allows for the identification of potential therapeutic targets.
Here, we identify that lncRNA ZFAS1 is increased in colon adenocarcinoma compared to
normal colon epithelium, and that ZFAS1 is principally located in the cytoplasm compared to the
nucleus of 3 colon adenocarcinoma cell lines. To further characterize ZFAS1, we performed a
number of different functional experiments, which demonstrated that ZFAS1 knockdown leads to
reduced cellular proliferation and migration. From a mechanism perspective, ZFAS1 was
predicted to have a direct binding relationship with miR-200b and miR-200c. As expected,
ZFAS1 had a reciprocal relationship with both miR-200b and miR-200c. Finally, ZFAS1 was
able to regulate ZEB1 expression, and was able to regulate the epithelial marker E-Cadherin and
the mesenchymal marker, Vimentin. The results of these experiments indicate that ZFAS1 is a
regulator of the EMT process. A summary of the results of these experiments is shown in Figure
45.
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Figure 45. Summary of dissertation findings. The lncRNA ZFAS1 which was identified to be differentially expressed from the
exploratory RNA-seq analysis, is associated with tumor progression and changes in miR-200/ZEB1/E-Cadherin, vimentin signaling
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There are variable results with the examination of ZFAS1 in the literature.111 ZFAS1 has
previously been shown to have a tumor suppressive function in breast cancer by decreasing both
cell proliferation and migration.141,142 Examination of ZFAS1 in hepatocellular carcinoma has
shown that it can have both a tumor suppressive and oncogenic function through different
mechanisms. It can act as a tumor suppressor by regulating the methylation of miR-9 in
hepatocellular carcinoma143, but can also promote cancer metastasis through binding of miR150.135 However, the majority of studies demonstrate that ZFAS1 has an oncogenic function, in
that many of the studies indicate that ZFAS1 can regulate both proliferation and migration.134,144.
Recently, Chen et al. reported that ZFAS1 could regulate proliferation, migration, and invasion in
colorectal cancer.137 They showed that ZFAS1 could mediate this through indirect regulation of
VEGFA through direct binding with miR-150. The results of our experiments support the
functional data reported by Chen et al, in that ZFAS1 knockdown leads to decreased proliferation
and migration.
Nevertheless, we report a novel signaling association between ZFAS1 and miR-200b and
miR-200c. Interestingly, we also investigated the interaction with miR-150, but we did not find a
reciprocal change in expression, although Chen et al. reported that miR-150 had a direct binding
interaction with ZFAS1 in the HCT116 cell line. The HCT116 cell line is also microsatellite
instable and has lower expression of ZFAS1 than any of the three cell lines that we selected for
investigation.118,145 The HCT116 cell line may have a different transcript expression profile
compared to our three cell lines, which may account for this lack of a difference, however this
does remain unclear and requires further investigation.
Nevertheless, both sets of data support the concept that lncRNAs can have multiple
mechanisms of action, through different signaling cascades. This attribute has been described as
both a positive and negative aspect of their potential utility.146,147 On one hand, the multiple
mechanisms of action could reduce cancer aggressiveness through a number of different signaling
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pathways which has clear major benefits. However, as previously noted, lncRNAs have been
shown to have differential functions in different cancers, and often the exact mechanism through
which they mediate their effect can be difficult to discern. Therefore, considerable study of a
single lncRNA would be required prior to a potential clinical use. Overall, non-coding RNAs are
being investigated as a small molecule therapeutic strategy for different diseases. There are a
number of clinical trials exploring the use of microRNA and siRNA technology as a therapeutic
strategy.148 For example, miR-122 is a critical molecule in the survival of the hepatitis C virus in
the liver. As such, a novel small molecule targeting miR-122 has been shown to be effective in
reducing hepatitis C virus RNA levels in a phase 2 clinical trial.149 Similarly, a specific siRNA
directed against procollagen alpha delivered in lipid nanoparticles has shown to be effective in
resolving liver fibrosis in a murine model suggesting its potential therapeutic use.150 . Another
siRNA targeting the respiratory syncytial virus has been shown to reduce the risk of bronchiolitis
obliterans in patients post lung transplant.151 In the future lncRNAs and other non-coding RNAs
may have a major role in the therapeutic management of different diseases.
Many studies demonstrate that lncRNAs can be regulated by miRNA through the
competitive endogenous RNA mechanism, but few have demonstrated alternative regulators. SP1
transcription factor, SP1, has been shown to transcriptionally increase ZFAS1 in a number of
different cancer types.111 Interestingly, the transcription factors that regulate protein coding genes
are the same as those for non-protein coding genes.152 This suggests there is a further layer of
complexity in studying the relationship between lncRNAs and other protein coding genes with
modulation of specific transcription factors.
There are a number of challenges in studying lncRNAs, as they can have a diverse array of
mechanisms of action. However, their cellular location is an important indicator of their
mechanism of action. After selection of 3 lncRNAs for further investigation, only two (GAS5 and
ZFAS1) were significantly represented in the cytoplasm of the cell, which is in contrast to that of
147

PVT1 which was significantly expressed in the nucleus. This does suggest that both GAS5 and
ZFAS1 have a cytoplasmic mechanism of action, namely a competitive endogenous RNA
function, such as acting as a miRNA sponge. Although PVT1 is predicted to have miRNA targets,
it is more likely that its principal function is that of a nuclear mechanism of action, through DNA
repair and rearrangements and interacting with the proto-oncogene MYC, which is supported by
studies in the literature153,154 In addition, there is a challenge when examining lncRNAs, as siRNA
technology has minimal effect on lncRNAs located in the nucleus as the cellular machinery to
perform RNA interference is located in the cytoplasm, and siRNA has relatively poor function
against nuclear located lncRNAs.155,156
There are some areas of needed further investigation that are highlighted by the results of
these experiments. TGF-β is a major inducing agent of EMT51, and recent studies have
demonstrated that it can be secreted by macrophages and other immune cells in the tumor
microenvironment.157 The role of lncRNAs involved in promoting a less aggressive, epithelial
phenotype, could be investigated in the context of cytokines secreted in the tumor
microenvironment. This could be achieved through the use of transwell chambers, or by treating
colon adenocarcinoma cell lines with cultured macrophage secretions, as performed by Jahangiri
et al.94 Although our study demonstrates the role of ZFAS1 in signaling through regulation of
miR-200b and miR-200c, ZFAS1 has been shown to interact with a number of other miRNAs.
This indicates that there is significant investigation required to fully delineate the function of
ZFAS1 and other lncRNAs prior to their clinical use.
Although we selected lncRNAs that are increased in expression in colon cancer compared
to normal colon epithelium, there are a large number of lncRNAs that are downregulated in
expression. Due to their large size, stable transfection is challenging, but some investigators have
suggested the use of CRISPR-activation technology to stably increase the expression of a
lncRNA in vitro.158,159 There are 5 members of the miR-200 family and we have restricted our
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study to two of these, miR-200b and miR-200c as they have been experimentally verified to
interact with ZFAS1. Although miR200b, miR-200c, and miR-429 are part of the same functional
cluster, we did not examine the role of miR-429 as it appears not to be an experimentally
validated target of ZFAS1. Further studies could investigate the role of other members of the
miR-200 family in relation to ZFAS1. As previously mentioned many target molecules can be
regulated by multiple lncRNAs, but when this is considered in the context that lncRNAs can
regulate multiple different molecules, it will become important to study lncRNAs in signaling
networks. For example, both SPRY4-IT1 and SNHG6 both target miR-101 to regulate ZEB1 to
mediate EMT, but they have not been investigated together in the context of modulating one of
them.69,70
There are a number of limitations to this work. Although ZFAS1 knockdown is
associated with both functional changes and reciprocal changes in the miR-200/ZEB1/E-cadherin,
Vimentin signaling pathway, we have not definitively shown that that ZFAS1 is a regulator of
this signaling cascade. Further experiments, such as a dual knockdown of both ZFAS1, and miR200b or miR-200c, are required to investigate the role of ZFAS1 as a regulator of this signaling
pathway. As previously mentioned, lncRNAs can mediate an effect on a number of different
signaling pathways and we focused on a single signaling pathway to help delineate the
mechanism of action of ZFAS1. Therefore, further work is required to investigate the other
pathways through which ZFAS1 may be mediating an effect on colorectal carcinogenesis. While
the transcription factor SP1 is a known upstream regulator of ZFAS1, other reasons for the
increased expression of ZFAS1, such as copy number amplification were not explored.
In conclusion, we identified a group of lncRNAs that were significantly increased in
expression in colon adenocarcinoma compared to normal colon epithelium in an RNAsequencing data set. We verified that a lncRNA ZFAS1 can regulate EMT through a reciprocal
interaction with both miR-200b and miR-200c. Knockdown of ZFAS1 can lead to a less
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aggressive phenotype in colon cancer cell lines, reduction in the mesenchymal marker, Vimentin,
and an increase in the epithelial- marker, E-cadherin. This indicates that ZFAS is a major
regulator of the aggressiveness of cancer and could be a target for therapeutic intervention in the
future.
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APPENDIX: ABBREVIATIONS

EMT

Epithelial-Mesenchymal Transition

lncRNA

long non-coding RNA

miRNA

microRNA

mRNA

messengerRNA

CRC

colorectal cancer

miR

microRNA

ZEB1,2

Zinc Finger E-Box Binding Homeobox 1,2

E-cadherin

Epithelial cadherin

XIST

X-Inactive Specific Transcript

H19

Imprinted Maternally Expressed Transcript

MET

Mesenchymal-epithelial transition

UICLM

Upregulated In Colorectal cancer and Liver Metastasis

N-BLR

primate specific non-coding transcript

XIAP

X-linked Inhibitor of Apoptosis Protein

SPRY4-IT1

Sprouty RTK signaling antagonist 4-Itronic Transcript 1

Wnt

Wingless/Integrated

β -catenin

Beta-catenin

PlncRNA-1

“CBR3”-Carbonyl Reductase 3

TUG1

Taurine Upregulated 1

MMP9

Matrix Metalloproteinase-9

PGRN

Progranulin

KIAA119

Cell Migration Inducing Hyaluronidase 1
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UCA1

Urothelial Cancer Associated 1

mTOR

mammalian Target of Rapamycin

TWIST1

Twist related protein 1

CHRF

Cardiac Hypertrophy Related Factor

GALNT1

Polypeptide N-acetylgalactosaminyltransferase 1

SNHG7

Small Nucleolar RNA Host Gene 7

MALAT1

Metastasis Associated Lung Adenocarcinoma Transcript 1

EZH2

Enhancer of Zeste Homolog 2

HOXD-AS1

“HAGLR” HOXD Antisense Growth-Associated Long NonCoding RNA

AEG-1

Astrocyte Elevated Gene 1

HIF1A-AS2

Hypoxia Inducible Factor 1 Alpha-Antisense RNA 2

DNMT3A

DNA Methyltransferase 3 Alpha

HDAC

Histone Deacetylase

siRNA

small interfering RNA

CYTOR

Cytoskeleton Regulator RNA

CTD903

“DUXAP9” Double Homeobox A Pseudogene 9

lncTCF7

long non-coding Transcription Factor 7

PVT1

Pvt oncogene

TGF- β

Tumor Growth Factor Beta

LINC001133

Long Intergenic Non-Coding RNA 001133

SRSF-6

Serine/arginine Rich Splicing Factor 6

JAK-STAT3

Janus Kinase Signal Transducer and Activator of Transcription 3

BC200

Brain Cytoplasmic 200

lncRNA AB073614

lncRNA AB073614

CPS1-IT1

Carbamoyl-Phosphate Synthase 1 Intronic Transcript 1

LC-1

Light Chain 1

MAPK

Mitogen Activated Protein Kinase

ERK

Extracellular signal-Related Kinases
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BACNR

BRAF-Activated Non-Protein Coding RNA

MEK

Mitogen activated protein kinase kinase

NNT-AS1

NAD(P) Transhydrogenase Antisense RNA 1

SLC25A25-AS1

Solute Carrier Family 25 Member 25

SLUG

“SNAI2” Snail Family Transcription Repressor 2

SNAIL

“SNAI1” Snail Family Transcription Repressor 1

SNGH15

Small Nucleolar RNA Host Gene 15

lncRNA-ATB

lncRNA Activated by TGF-β

LINC00959

Long Intergenic Non-Coding RNA 00959

FOXD2-AS1

Forkhead Box D2 Antisense RNA 1

HOTAIR

HOX Transcript Antisense RNA

HOXA-AS2

Homeobox A cluster Antisense RNA 2

ZFAS1

ZNFX1 Antisense RNA 1
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